

The Humane Society Institute for Science and Policy

WBI Studies Repository

12-2010

An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 2. Alternative Replacement Methods

Jarrold Bailey

New England Anti-Vivisection Society

Follow this and additional works at: https://www.wellbeingintludiesrepository.org/acwp_arte



Part of the [Animal Experimentation and Research Commons](#), [Animal Studies Commons](#), and the [Other Medical Sciences Commons](#)

Recommended Citation

Bailey, J. (2010). An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. *ATLA-Alternatives to Laboratory Animals*, 38(6), 471.

This material is brought to you for free and open access by WellBeing International. It has been accepted for inclusion by an authorized administrator of the WBI Studies Repository. For more information, please contact wbisr-info@wellbeingintl.org.



An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 2. Alternative Replacement Methods

Jarrod Bailey

New England Anti-Vivisection Society, Boston, MA, USA

Summary — The use of chimpanzees in hepatitis C virus (HCV) research was examined in the report associated with this paper (*1: Validity of the Chimpanzee Model*), in which it was concluded that claims of past necessity of chimpanzee use were exaggerated, and that claims of current and future indispensability were unjustifiable. Furthermore, given the serious scientific and ethical issues surrounding chimpanzee experimentation, it was proposed that it must now be considered redundant — particularly in light of the demonstrable contribution of alternative methods to past and current scientific progress, and the future promise that these methods hold. This paper builds on this evidence, by examining the development of alternative approaches to the investigation of HCV, and by reviewing examples of how these methods have contributed, and are continuing to contribute substantially, to progress in this field. It augments the argument against chimpanzee use by demonstrating the comprehensive nature of these methods and the valuable data they deliver. The entire life-cycle of HCV can now be investigated in a human (and much more relevant) context, without recourse to chimpanzee use. This also includes the testing of new therapies and vaccines. Consequently, there is no sound argument against the changes in public policy that propose a move away from chimpanzee use in US laboratories.

Key words: *chimpanzee, hepatitis C, hepatitis C virus, hepatocellular carcinoma, Pan troglodytes.*

Address for correspondence: *New England Anti-Vivisection Society, 333 Washington Street, Suite 850, Boston, MA 02108-5100, USA.*
E-mail: jarrod.bailey@mac.com

Introduction

Hepatitis C affects hundreds of millions of people worldwide, including an estimated four million in the USA and five million in Europe (1–3). Serious consequences include liver cirrhosis and hepatocellular carcinoma (HCC), and around 5% of infected people eventually die as a result (4–6). It is therefore a significant healthcare burden, which is set to increase dramatically as the number of infected people rises (2). Research to understand the virus and the disease has been a priority since its discovery in 1989 (7), and this research has involved extensive use of chimpanzees.

However, invasive research involving the use of captive chimpanzees has been banned, or at least severely restricted, across much of the world (8). The continued use of chimpanzees in invasive research in the USA is therefore highly controversial, and there exist compelling arguments against it — for example, the extent of suffering of those chimpanzees involved, and concern over the lack of human relevance of the data produced (8–17). The latter — i.e. the scientific validity of chimpanzee experimentation with respect to human medicine — has been extensively investigated with respect to hepatitis C in the associated paper, *1: Validity of*

the Chimpanzee Model (18). This previous paper, which examined, in detail, claims concerning the past contributions of chimpanzee experiments to hepatitis C research, as well as the need for chimpanzee use in current and future investigations, concluded that these claims were exaggerated and unjustifiable, respectively. Major scientific, ethical, economic and practical caveats of the chimpanzee model in hepatitis C virus (HCV) research were highlighted, and the contributions of other, non-chimpanzee methods of research were evaluated. On balance, it was concluded that extensive chimpanzee use in the study of the virus and the disease has made relatively negligible contributions to the body of knowledge and to tangible progress, as compared to non-chimpanzee methods, and that the chimpanzee model must be considered to be scientifically redundant, given the array of alternative methods of inquiry now available.

While Paper 1 makes this argument in its own right by evaluating the degree to which chimpanzee data are predictive of and relevant to human HCV infection, and by illustrating the extent of the contribution of other methods, this complementary paper makes an important further contribution, by reviewing the breadth and com-

prehensive nature of non-chimpanzee methods, and illustrating how *in vitro* approaches, supported by clinical, epidemiological, *ex vivo* and *in silico* methods, can provide all the necessary information about HCV and its pathology to enable the development and testing of HCV therapies.

In Vitro Systems to Study HCV

In the search for a more complete understanding of the HCV life-cycle, in order to facilitate the discovery of new therapeutics, one thing above all else has been cited as a serious impediment and rate-limiting factor, namely, the lack of a reliable and robust cell culture system (e.g. 1, 19–28). This is not surprising, as cell and viral culture are acknowledged as having been pivotal in the development of vaccines against other viruses, such as the polio and measles viruses (29, 30). This is because cell culture approaches, among other things:

- permit the investigation of the entire viral life-cycle, from host-cell attachment and entry, through replication, to the assembly and release of progeny virions;
- facilitate reverse-genetics analyses to elucidate detailed information about viral genomics and proteomics, including interactions with host factors;
- permit the study of the humoral immune response and neutralising antibodies to aid vaccine development; and
- greatly assist in the identification of therapeutic targets and in the screening and testing of anti-viral compounds (1, 27, 31).

In view of their importance, many attempts have been made to establish cell culture systems for HCV. As relatively long ago as 2001, reviews cited dozens of systems that had been assessed and that had succeeded to varying degrees (25). More recently, many good reviews have outlined developments in this field and have illustrated the major breakthroughs these represent and the insights and progress they should deliver (1, 27, 32–34).

Infection of cultured cells with HCV

The simplest approach involves the straightforward infection of primary human cell cultures with HCV-infected sera. This has been successfully achieved with primary fetal (28, 35, 36) and non-fetal (37, 38) human hepatocytes and primary human peripheral blood mononucleocytes (PBMCs; 39). While some investigators reported that the

efficiencies of these systems could be low and/or hard to control, others described relatively long-term, reliable, efficient and reproducible systems that supported HCV infection and replication. These successes were reflected in opinions that this approach constitutes a valuable model for the study of HCV replication, the identification of relevant viral and cellular factors associated with successful infection, the evaluation of antiviral agents, the further analysis of serum infectivity, and the cloning of novel HCV genomes from patients (28, 37, 38).

At the same time, various immortalised cell lines were exhibiting support of HCV infection and replication, such as the human T-lymphocyte and B-lymphocyte cell lines MOLT-4Ma, HPB-Ma, MT-2, and Daudi (25, 40, 41). Some of these cell lines were able to support long-term (≥ 12 -month) infections (42, 43), and demonstrated a good correlation of their measured infectivity titres with the infectivity titres measured in chimpanzees (42). The immortalised human hepatoma cell lines, HepG2, Huh-7 and PH5CH (25, 44, 45), also supported HCV infection and replication, and efforts to increase the efficiency of these and the lymphocyte-based systems led to the culture of primary hepatocytes and PBMCs from persistently-infected patients (46, 47) that produced higher viral titres. Research involving infected cell lines such as these has led to some important discoveries, and progress was being realised in improving cell culture conditions and performance. For instance, this approach revealed that the low-density lipoprotein receptor (LDLR) is involved in the process of HCV entry into the host cell (48), and a human B-cell line, SB, was shown to continuously, reliably and reproducibly produce infectious HCV virions, which were subsequently able to infect a number of human cell lines, including hepatocytes *in vitro*, potentially facilitating the study of the entire viral life-cycle (49). However, by the time these discoveries were made, these culture systems were generally not deemed robust enough to support reliable in-depth studies of the HCV life-cycle and the development of anti-viral agents. This, combined with the difficulty of sourcing and maintaining primary cells, and the desire to create a system that enabled infection with defined HCV genomes to facilitate reverse genetics studies, meant that attempts at viral culture had progressed from using virus-containing sera or infected cells to the use of HCV molecular clones.

Infectious molecular clones of HCV

As one of the more salient examples put forward by advocates of chimpanzee research of the importance of chimpanzees as a research tool, a thorough account of the development and use of

infectious molecular clones in HCV research is given in the associated paper (18). In summary, HCV clones are produced *in vitro* by using HCV genomic RNA from infectious serum samples as a template. These clones then serve as templates for the production of RNA molecules with precise 3' termini, representing HCV genomic RNAs (50), which can be used *in vitro* or *in vivo* to initiate the viral life-cycle (32). To overcome the initially unsuccessful attempts which utilised screened clones to infect chimpanzees (51, 52), lessons were learned from previous work with other related viruses (e.g. 53), in which *consensus* sequences of the specific viral isolates being used were determined, in order to overcome mutation effects (54–56). While it has been asserted that the development of infectious clones was dependent on chimpanzee use (22, 24), there existed several contemporaneous *in vitro* approaches for which investigators had claimed validity for the study of the HCV life-cycle, including replication, persistence and pathogenicity, and to test anti-viral agents (57, 58). It had been claimed that problems existed with regard to the measurement of HCV replication in these *in vitro* systems (59), but a number of sensitive and reliable methods were actually available, to specifically detect and quantify HCV replicative activity. For example:

- the reverse transcription-polymerase chain reaction (RT-PCR) and/or ribonuclease protection assay of negative strand RNA intermediates only produced during viral replication;
- the incorporation of radioactive nucleosides, such as [³H] uridine, into *de novo* RNA molecules;
- the *in situ* RT-PCR of HCV RNA present in long-term cultured cells;
- the infection of freshly cultured non-infected cells with culture medium from transfected cell lines, indicating the production of infectious HCV;
- the immunostaining of viral proteins; and
- the visualisation of virus or virus-like particles via electron microscopy (57, 58).

Furthermore, recent examinations of 14 HCV clones and their properties *in vitro* and *in vivo* (54, 59) list parallel references for the *in vitro* and *in vivo* studies of each HCV clone. Finally, it may be true that the existence of an established *in vivo* system which used chimpanzees for determining the clone infectivity of other viruses, led to the continuation of chimpanzee use out of convenience, rather than necessity (52).

While chimpanzees continued to be used to investigate the characteristics of HCV infectious clones, many *in vitro* approaches were highly informative. For example, with regard to the HCV proteins, *in vitro* studies furthered our under-

standing of sub-cellular localisation and assembly (60–63), function (60, 64), effects on host-cell growth and gene expression (65, 66), and effects on IFN-induced intracellular signalling (67). Such approaches had also elucidated the anti-viral effects and modes of action of interferon (IFN) and ribavirin (68, 69), the role of CD26 in HCV infection (70), the determinants of membrane association of the viral polymerase (71), and various properties and characteristics of the HCV NS3-NS4A complex (72).

Subgenomic and genomic replicon systems

Replicons (autonomously replicating HCV-derived RNAs) perhaps represented the first highly reliable, reproducible and robust *in vitro* method to investigate HCV replication. Their development was considered a “great leap forward” (1), a “significant advance” (31), a “milestone” (27), and a “highlight” and a “major breakthrough” (50), which greatly facilitated research into many aspects of the HCV life-cycle. The importance of replicons is reflected in their citation, alongside full recombinant HCV culture, in discussions of the crucial contributions *in vitro* approaches have made to HCV research (6, 27). These contributions include, for example, the elucidation of the roles of specific HCV genome segments and proteins in replication, the determination of intracellular HCV protein localisation, the characterisation of virus–host interactions, and the identification of anti-viral agents (20, 32–34, 73–75). Many more examples, too numerous to discuss here, are summarised in a recent very detailed and comprehensive review, including, for example, the importance of the HCV untranslated regions (UTRs) and other *cis*-acting elements in viral replication, the elucidation of roles, functions and criticality of HCV viral proteins and protein domains, the involvement of various host proteins with the endoplasmic reticulum, the association of the HCV core protein with host lipids, and the screening and testing of viral inhibitors (1).

Subgenomic replicons comprise truncated viral minigenomes containing, for instance, the HCV 5' and 3' UTRs plus the viral polymerase gene, but also direct the synthesis of a marker gene (such as the neomycin resistance gene). This permits the selection of stable cell lines containing highly replication-competent HCV RNAs (1, 50). Their development, which notably was contemporary to, and independent of, experiments involving infectious molecular clones in chimpanzees, was based on prior experiments involving the related *Flaviviridae* Kunjin virus (76), the bovine viral diarrhoea virus (BVDV) (77), and poliovirus (78), in which transcripts from subgenomic molecular clones were shown to be capable of autonomous intracellular replication *in vitro*.

The first subgenomic replicon for HCV was based on a consensus genotype 1b sequence derived from a chronically infected patient, and exhibited efficient replication when transfected into Huh7 human hepatoma cell lines (26). Subsequent *in vitro* analyses revealed the evolution of various adaptive mutations in the subgenomes, which further increased their replicative capacities by several orders of magnitude, even up to 10,000-fold (33, 79, 80). Knowledge of these adaptive mutations permitted the development of extremely efficient *in vitro* replicon systems, which rendered the inclusion of selectable marker genes redundant. The consequent exclusion of heterologous RNA from replicons, among other things, led to a further increase in replication efficiency (81), facilitated the study of unmodified HCV replicons in a more 'native' environment, assisted the development of full-length replicon systems (82) — including those involving other HCV genotypes (e.g. 1a [81] and 2a [83]), and opened the door to the *in vitro* investigation of full viral assembly (1). Furthermore, it was discovered that the cell line itself — even different passages of the same cell line — could affect replication efficiency by up to 100 times (84), and that 'curing' cell lines of HCV RNA via IFN treatment could lead to subsequent higher permissiveness (85). The identification, isolation and use of highly permissive cell lines have also facilitated the use of the replicon system by increasing efficiency. Examples of these cell lines include the Huh7.5 (85), Huh7.5.1 (33) and Huh7-Lunet (86) lines.

Whilst replicon systems were proving to be extremely valuable for research into most aspects of the HCV life-cycle, they were proving unsuitable for the investigation of viral assembly and release. Although full-length replicons were able to produce HCV viral proteins, many did not produce detectable progeny virions — presumably due to adaptive cell culture mutations favouring replicon replication at the expense of viral assembly and release (1). However, some systems did reliably produce infectious progeny virions (87), despite this being at a low level (1). Fortunately, alternative and highly productive *in vitro* approaches to this type of study have been developed. The use of HCV virus-like particles (VLPs) and HCV pseudoparticles (HCVpp) has been productive, and *trans*-encapsidation of HCV subgenomic replicons has been achieved via the baculovirus-directed expression of HCV structural proteins (88), the generation of a packaging cell line (89), and the use of helper viruses (90).

HCV virus-like particles (VLPs) and HCV pseudoparticles (HCVpp)

There are a number of detailed and extensive recent reviews of the application of these methods

to HCV research, and of the data they can provide with regard to HCV binding, membrane fusion and entry, antibody-mediated neutralisation, screening of anti-HCV agents and vaccine development, and other aspects of the HCV life-cycle (1, 27, 33). Briefly, the techniques range from the simple expression of the HCV envelope glycoproteins (E1 and E2) in cell culture, through the expression of HCV structural proteins by using recombinant baculovirus, to the creation of HCVpp in which the HCV envelope proteins are incorporated into other enveloped viruses, in place of their own envelope proteins.

Experiments involving the expression of HCV envelope proteins in cell lines implicated the CD81 cell-surface protein and scavenger receptor class B type I protein (SR-BI) as mediators, for example, of HCV attachment and entry (91–93). However, more-advanced investigations with *bona fide* VLPs were more productive, permitting detailed *in vitro* studies of virion assembly, genome encapsidation, virus–host interactions and vaccine research.

VLPs were first reported following the expression of HCV structural proteins by using the eukaryotic baculovirus expression system, whereby these proteins self-assembled into enveloped VLPs with highly similar biophysical properties to virions isolated from HCV-infected humans (94). These VLPs have been subsequently used in a number of ways. For example:

- to elucidate humoral immunity in acute and chronic hepatitis C patients, including responders and non-responders to IFN therapy (95);
- to determine structural differences in HCV envelope proteins, depending on their context, and consequent effects on CD81 binding (96, 97);
- to study early events in host-cell entry, including the role of lipoproteins (98, 99) and low-density lipoprotein (LDL) receptors (100);
- to demonstrate the role of cell-surface heparan sulphate proteoglycans (HSPGs) in HCV envelope–target cell interaction (101), and to map the viral and cellular determinants of this interaction (102);
- to establish the crucial involvement of the claudin-1 (CLDN-1) protein late in the viral entry process (103);
- to study HCV uptake, antigen processing and presentation in human dendritic cells (104); and
- to analyse the genome-wide host-cell response following HCV binding of human liver and hepatoma cells (105).

Infectious HCVpp contributed to the study of early events in HCV infection further, as, unlike

VLPs, HCVpp are infectious and permit the functional investigation of putative receptors involved in cell entry (106). HCVpp are formed via the transfection of human cell lines with: a) expression vectors encoding the HCV envelope proteins (E1 and E2); b) a 'viral genome' that can be encapsidated, which contains a reporter gene such as the green fluorescent protein; and c) a 'packaging construct' encoding core proteins from another enveloped 'carrier' virus, such as murine leukaemia virus (MLV; 106) or human immunodeficiency virus (HIV; 107). Upon expression within the cell of the transfected constructs, assembly of the hybrid virion occurs, which comprises an encapsidated RNA 'genome' containing the reporter gene, with the HCV envelope proteins at the virion surface. These HCVpp are secreted into the culture medium and can be subsequently used in assays for infectivity, since they are easily quantifiable via the measurement of reporter gene expression (106–109).

HCVpp systems are robust and reliable, and have therefore facilitated many important discoveries in HCV research, including the elucidation of HCV tropism, the identification of HCV envelope glycoproteins and host-cell receptors/co-receptors, and the determination of their involvement in the infection process. Also, HCVpp systems have permitted measurement of the extent of neutralisation by patient sera and monoclonal antibodies, leading to the mapping of envelope protein neutralisation epitopes, which is highly relevant to vaccine studies (for extensive and comprehensive reviews, see 1, 33, 110–112). For example, HCVpp experiments involving a variety of HCV envelope proteins of different genotypes have:

- demonstrated the effects on HCV infectivity of lipoproteins such as high-density lipoproteins (HDL) and low-density lipoproteins (LDL) (113–119);
- permitted the analysis of cross-neutralisation, as well as genotype-specific neutralisation (106, 119–125); and
- elucidated the roles of CD81 (92, 107, 114, 126–129), SR-BI (107, 114, 116, 118), clathrin (107, 114, 130–132), claudin-1 (103), C-type lectins (133, 134), and pH (107, 114) in viral attachment and entry.

Overall, the HCVpp system was clearly technically uncomplicated, versatile, highly productive and an extremely important facet of HCV research. However, HCVpp involve chimaeric virions and can only be used to investigate the early steps of the infective process. Therefore, a more native, physiologically relevant and comprehensive 'full life-cycle' system was still required.

Full life-cycle infectious HCV cellular clones (HCVcc)

The above information underscores the progress made in the development of *in vitro* techniques to study the life-cycle of HCV and identify antiviral therapies (33). A suite of approaches involving HCV-infected primary and immortalised cell lines, subgenomic and full-length replicons, and HCV VLPs and pseudoparticles, facilitated the investigation of many aspects of the virus and the disease — for example, virus attachment and entry into host cells, its replication and the assembly of progeny virions, host defences against HCV infection, host–virus interactions, immune escape, and the screening of anti-viral agents. Each method has some limitations. For instance, primary cell culture can be demanding, and replicons harbour adaptive mutations. Also, VLPs are not secreted by host cells, and HCVpp are hybrids with non-HCV cores, and they are not associated with lipoproteins (33). A full life-cycle system was therefore necessary, in which all aspects of HCV infection, including reverse genetics studies, could be investigated more easily and more reliably, all in the context of the complete viral life-cycle.

The major breakthrough in the ultimate realisation of HCVcc was made in 2005, when the development of the first *in vitro* system supporting the infection, replication and production of infectious HCV virions was announced (135). This system utilised the genotype 2a clone, JFH1, derived from an HCV isolate obtained from a Japanese patient with fulminant hepatitis (136), which was transcribed *in vitro* and the RNA transfected into Huh7 cells. This was based on earlier experiments involving a JFH1 subgenomic replicon, which, unlike all similar replicons, did not require adaptive mutations in order to be highly replicative in a number of different cell lines (83, 137, 138). The presence of adaptive mutations in replicons had been widely assumed to favour replication at the expense of the formation of viral progeny (74, 139). It was therefore hypothesised that these JFH1 replicons might be more conducive to the formation of new virus particles — hence the successful experiments of Wakita *et al.* (135).

Subsequent investigations greatly improved this culture system. The transfection of other cell lines, such as Huh7.5 and Huh7.5.1, with JFH1 transcripts resulted in increased replication and viral titres, in systems that could be initiated at low multiplicities of infection, serially passaged, and which reflected the clinically-observed effects of IFN treatment (140, 141). Furthermore, the construction of JFH1 chimaeras with other HCV isolates, such as J6, Con1 and H77S, has also improved efficiency (140, 142, 143), and has succeeded both for intragenotypic chimaeras as well as intergenotypic chimaeras — the latter being crucial for research

into other HCV genotypes and the development of anti-viral therapies against them (144–146). The serial passage of Huh7.5 cells infected with chimeric J6/JFH1 HCV has given rise to culture variants with adaptive mutations, which demonstrate enhanced infectivity, and which could be useful for the study of HCV entry (147). Dedicated systems for HCV genotype 1a (strain H77 [87]) and 4a (148) also exist, and are showing promise. In addition, alternative systems involving the transfection of DNA plasmid clones instead of RNA transcripts are also in the course of development for HCV genotype 1a, 1b and 2a strains. In these systems, intracellular ribozyme-directed cleaving of transcripts produces functional viral RNA molecules that give rise to HCV particles for each strain (149).

While these HCVcc systems are relatively recent developments, they have already been used to provide useful data on the life-cycle of the virus. They have corroborated with and expanded upon HCV receptor experiments, by illustrating, for example, that HDL and the CD81 and SR-BI proteins are required for HCV infection (150–154), and that viral entry is mediated by clathrin vesicles (130). HCVcc have also demonstrated the close association of apolipoprotein C1 (ApoC1) with HCV. ApoC1 associates with HCV intracellularly via its C-terminus during viral morphogenesis, and plays a crucial role in HCV infectivity (155). HCVcc have also shown, via small interfering RNA (siRNA) analysis of 140 cellular-membrane trafficking genes, that HCV replication utilises host gene products involved in cytoskeletal regulation and endocytic trafficking, and also a critical lipid kinase PI4K-IIIalpha (156).

Summary and outlook of *in vitro* systems

Current consensus endorses and validates the assertions that cell culture systems were imperative for the progress of HCV research. Given the realisation and continued development of the *in vitro* methods summarised here, the prospects for further significant advances in the understanding of HCV, its life-cycle, the ensuing pathology, and prophylactic and therapeutic therapies, are substantial and unprecedented (1). The full life-cycle of HCV is now easily accessible to reliable and reproducible *in vitro* study. While the use of cellular clones represents the current vanguard, other more-restricted, yet more-focused, systems are still widely used and are delivering important data. Allied technologies, such as genomics and proteomics, will augment these methods further, providing enhanced detail of virus–host interactions and the molecular basis of resistance and progression to chronicity, thus illuminating putative targets of new anti-virals and vaccines. There is still scope for improvement in HCVcc systems, however. Higher viral titres and a broader range of

host cells are desirable, while extension of HCVcc to genotypes other than 2a is crucial. It has recently been established that primary and passaged cultures of human fetal hepatocytes (HFH) support the replication of unmodified HCV (i.e. devoid of adaptive mutations) for up to two months (28), either following the transfection of consensus transcripts of HCV strain H77 (genotype 1a; 51) or infection with patient sera containing HCV of various genotypes, including 1a, 1b, 2a, 2b and 3. Progeny viruses were also released into the culture supernatants and proved to be infectious. This system is extremely stable and reproducible, as HFH cells maintain their phenotype for months and express LDL receptor and CD81, which play important roles in the HCV life-cycle.

***In Vitro* & Clinical Findings in HCV Research**

Recap

A great many examples of crucial *in vitro* and clinical findings concerning HCV infection have already been discussed above. Infected primary cell lines implicated the LDL receptor in HCV entry. Subgenomic and full-length replicon systems have elucidated:

- the subcellular localisation of HCV proteins and their assembly into VLPs;
- the functions of wild-type and mutant HCV proteins;
- the effects of HCV proteins on host-cell growth and gene expression;
- the functional roles of HCV UTR stem-loops;
- the anti-viral effects and modes of action of IFN and ribavirin;
- the role of CD26 in HCV infection;
- the effects of HCV proteins on IFN-induced intracellular signalling;
- the determinants of membrane association of the viral polymerase;
- various properties and characteristics of the HCV NS3-NS4A complex;
- the roles of specific HCV proteins and genome segments, including UTRs and other *cis*-acting elements in replication;
- virus–host interactions;
- the identification and testing of anti-viral agents; and
- the association of the HCV core protein with host lipids.

HCV VLPs and HCVpp have greatly informed our understanding of:

- HCV attachment, membrane fusion and entry;
- virion assembly, genome encapsidation and virus–host interactions;
- the involvement of CD81, SR-BI, LDLRs, HSPGs and CLDN-1 in the viral life-cycle;
- the genome-wide host-cell response following HCV binding to human liver and hepatoma cells;
- antigen processing and presentation in human dendritic cells; and
- antibody-mediated neutralisation and other aspects of humoral immunity in acute and chronic hepatitis C patients.

HCV VLPs and HCVpp have also facilitated the screening of anti-HCV agents and potential vaccine development, including the mapping of envelope protein neutralisation epitopes, which was crucial for vaccine studies.

HCVcc have augmented and corroborated much previous work with VLPs and HCVpp, and have further informed our understanding of the roles of clathrin vesicles, ApoC1, and many host genes in the HCV life-cycle. Human studies were vital from the inception of HCV research, demonstrating that ‘non-A, non-B hepatitis’ (NANBH) was the salient complication of transfusion therapy, defining NANBH’s natural history, identifying surrogate markers of the disease, such as alanine aminotransferase, and, as a result of these studies, lowering the incidence of transfusion-associated NANBH, even prior to the definitive identification of HCV.

Studies of people with hepatitis C have been, and continue to be, extremely valuable and informative (reviewed by Seeff [157]). Several clinical studies, some of which utilised human liver biopsies, and some of which were prospective (thus enabling the study of early infection in asymptomatic HCV-positive people), have elucidated the roles of cellular and humoral immunity during acute HCV infection and viral clearance, and following recovery. These studies revealed the importance of HLA alleles, the role of IFNs, and the genetic mechanisms and miRNAs associated with infection, progression to fibrosis, viral clearance and the outcomes of IFN therapy, in both responders and non-responders.

The power and potential of ‘alternatives’ — further examples

Analysis of HCV structure and physical properties

Electron microscopy and immunoelectron microscopy of patient sera are helping to inform our

understanding of the structure and morphogenesis of the virus (158–163), and molecular analyses of human sera have revealed the association of HCV virions with lipoproteins and immunoglobulins (164–170). Although some subsequent infectivity studies have involved the use of chimpanzees (171, 172), there are many other studies that have described the association of lipoproteins and apolipoproteins with HCV (and the consequences of this association), that did not use chimpanzees. These were based instead, for example, on HCVpp studies (116, 118, 119) and physicochemical, immunological and electron microscopical studies of human sera (165, 169, 173–175). HCVcc systems have also been useful, by revealing, for example, the determinants of interactions between HCV NS5A and HCV core proteins, and their subcellular localisations (176).

Pathogenesis/viral clearance and persistence

Prospective clinical studies permit the study of early events in infection and at disease onset, including the recognition of spontaneous resolution, and allow the pairing of ‘matched controls’ for comparative studies. Both prospective and retrospective studies have generated important data on disease progression, such as rates of fibrosis, cirrhosis, HCC, and death. So-called retrospective-prospective studies take advantage of serendipitous discoveries of distant, well-characterised, point-source outbreaks of hepatitis C, where data from all infected persons are recoverable and the subjects can be followed prospectively. Some of these studies have allowed follow-up periods of up to 35 years (177), and have revealed that infected children and young women had the highest rates of spontaneous resolution, along with the lowest rates of development of cirrhosis and HCC, and of death from liver disease. These studies also revealed that individuals who are immune suppressed, and those who are infected but who have normal aminotransferase levels, progress at very different rates (157). Human studies have also shown that:

- there might be no correlation of HCV-specific T-cell responses with viral clearance, in contrast to previous reports (178);
- strong CD8⁺ T-cell responses are not sufficient to prevent progression to chronicity (179–181);
- mutations in HLA class I-restricted epitopes targeted by CD8⁺ cells occur early in HCV infection and are associated with persistence (182);
- particular HLA class I alleles were associated with viral clearance or persistence in a cohort of women accidentally infected with HCV (183); and

— an increase in the diversity of the viral population (evolution of quasispecies) is associated with progression to chronicity via immune evasion (184).

Human and *in vitro* studies have revealed that inadequate cellular immunity might be a factor in HCV persistence and the development of chronic hepatitis C (185, 186), and that viral employment of ‘decoy’ antigens (187) or inhibition of host IFN responses could be involved in this process (188, 189).

Studies of neutralising antibodies, immune escape and the roles of immune responses in HCV infection and clearance have been, and continue to be, greatly aided by clinical and *in vitro* approaches. Some HCV-infected patients with primary antibody deficiencies have accelerated rates of disease progression (190). Observations that HCV infection might not induce protective immunity were made in a study of thalassaemic children (191), while studies with hypogammaglobulinaemic humans indicated that antibodies were not required for HCV clearance (192) — a finding corroborated in a prospective study of prisoners, some of whom spontaneously cleared HCV, but never developed anti-HCV antibodies (178, 193, 194).

HCVcc systems have revealed the role of cholesterol and sphingolipid in HCV infection and virion maturation (176), the molecular mechanisms by which the HCV core protein triggers hepatitis-associated neoangiogenesis (195), and the mechanism of the role of HCV NS2 protein in viral assembly (196). Magnetic absorption of HCV virions (HCVcc) and/or HCVpp to nanoparticles enables a synchronous infection to be induced via the natural entry route of HCV. This is important for both the accurate determination of the kinetics of viral entry and subsequent viral and cellular events (including the early stages of infection), and the improvement of efficiency and infectivity (197). Microarray studies have also been used in tandem with siRNA analyses and with HCVcc systems, in order to identify genes whose expression is altered by HCV, which are important to pathogenesis, and which contribute to hepatocellular damage. Arginase I, for example, is elevated following HCV infection, and stimulates hepatocellular growth (198). Serial analysis of gene expression (SAGE) techniques have also been applied to the study of gene expression profiles in human hepatitis C and HCC livers. These techniques have identified many different genes and genetic pathways involved in HCV infection and pathogenesis (199).

Various *in vitro* methods, allied with replicon and HCVcc systems, have permitted the study of the HCV NS2/3 and NS2 proteins, previously shown by HCVcc approaches to be necessary for HCV virion assembly and viral infectivity (200, 201). Via mutagenesis and ensuing alterations in NS2/3 degradation, the importance of NS2 regulation for the HCV viral life-cycle, and the identifica-

tion of specific regions and residues of NS2 for infectious virion assembly, were demonstrated (202, 203). High-throughput (HT) mutational analyses, making use of HCVcc, have also been applied to the entire HCV genome. This has permitted the profiling of HCV *cis*-elements and protein domains, confirming previously identified functional regions of the HCV genome (204). *In vitro* approaches have also revealed a number of different mechanisms by which viral proteins mediate IFN resistance (205). The tagging of HCV non-enveloped capsid-like particles with a fluorescent protein has permitted observation of the intracellular trafficking, in hepatocytes and various human immune cells, of naked capsids via live microscopy (206). This should increase our understanding of their biological significance and their role in pathogenesis (206). Cell culture, patient-based research, and a variety of *in vitro* data, have all highlighted a role for the HCV Alternative Reading Frame Protein (ARFP; also known as F [frameshift] and core+1) in the HCV life-cycle, and implicated it in HCV-related advanced liver disease and HCC (207).

Genome-wide association studies (GWASs) are accelerating, thanks to improved genotyping and single-nucleotide polymorphism (SNP)-discovery technologies. By scanning maps of genetic markers to identify differences in allele frequency between hepatitis C patients and appropriate controls, genomic regions affecting HCV infection and hepatitis C pathology can be identified, adding important new data to our knowledge of HCV pathophysiology and pharmacology (208). For example, a GWAS involving several hundred patients scanned more than 12,000 genes to discover greater than 1,600 SNPs associated with advanced HCV-related fibrosis (209). Of these, two SNPs were considered to be significantly associated with advanced fibrosis, and another SNP with decreased risk of advanced fibrosis. These markers should be important in predicting fibrosis risk in HCV patients. Furthermore, 361 of the discovered SNPs were selected for ‘signature building’, leading to a predictive signature for cirrhosis in Caucasian patients (208), and a seven-gene signature to differentiate high risk and low risk of cirrhosis (210).

Proteomic technologies have had a major impact in advancing virology in general, and are believed to be a key approach to elucidating the pathogenesis of many viruses, including HCV (reviewed by Liu *et al.* [211]). For example, MALDI-TOF mass spectrometry and liquid chromatography–tandem mass spectrometry (LC-MS/MS) have been used to analyse hepatoma cell lines to identify proteins involved in the pathogenesis of HCV that contribute to its carcinogenic properties, and (in conjunction with the yeast two-hybrid system) to identify host receptors and other virus protein–host protein interactions (211).

Host factors and response

Prospective and retrospective clinical studies have also identified numerous host factors that influence disease progression. These include:

- age (4, 177, 212–214), gender (4, 213, 215–217) and race (218, 219);
- genetic polymorphisms in HLA (220, 221) and profibrogenic cytokine (222, 223) genes;
- metabolic factors, in patients with steatosis (224, 225), diabetes (226, 227) and obesity (228, 229); and
- co-infection/co-morbidity associated with HIV (230–234), hepatitis B (235, 236), schistosomiasis (237, 238) and haemochromatosis (239), as well as smoking (240, 241) and high alcohol intake (242–244).

Microarray studies of human liver core needle biopsies have been “extensively utilised for global transcriptional profiling of the host response to HCV infection from a variety of disease states including fibrosis, cirrhosis and hepatocellular carcinoma” (245–251; as reviewed by Walters & Katze [6]). RNAi screening, by using siRNAs, permits the analysis of specific ‘knockdowns’ of host genes, in order to determine their effects on (and the role of those genes in) viral infection (252, 253). By coupling an siRNA-based cell-array screening system with HT fluorescence microscopy, an automated method of analysing images of single cells has been developed that can identify cells with altered HCV infections (254, 255). This permits the quantification of viral replication and the identification of genes involved in replication and viral entry. *In vitro* methods have provided considerable data on the importance of microRNAs (miRNAs) in the liver during HCV infection. For example, they have been shown to regulate the expression of HCV transcripts, acting as important cofactors or inhibitors, assembling into RNA-induced silencing complexes. They are affected by IFNs, and so act as targets for anti-viral therapies, and they differ between non-responders and early-responders to IFN therapy (256). A functional screen of a small hairpin RNA (shRNA) library, in concert with siRNA knockdown experiments, identified cellular factors involved in regulating the replication of HCV subgenomic replicons. The host-cell lipid kinase PI4KIII- α (produced by the *PI4KA* gene) was shown to be essential for the replication of all HCV genotypes tested (1a, 1b and 2a; 257). The results of these studies are augmented and corroborated by other *in vitro* and clinical analyses, which establish the genes/proteins as genuine therapeutic targets (e.g. 258–261). These include, for example, real-time quantitative RT-PCR, a technique that has permitted very accurate and quantitative gene expression analysis in hepatitis

C patients, leading to “new insights into the role of gene networks and regulatory pathways” in hepatitis C and the development of fibrosis and HCC (246, 247). This technique has been used to establish that DNA methylation of specific genes is an important event preceding cirrhosis and HCC (208, 262–267). It has also facilitated the investigation of differential miRNA expression in liver tissue from uninfected and HCV-infected patients, which revealed that pathways relating to immune response, antigen presentation, cell-cycle, proteasome, and lipid metabolism were each activated by HCV (268).

Replicon systems have demonstrated that:

- oxidative stress induces an anti-HCV status via the activation of the MEK–ERK1/2 signalling pathway, in response to various anti-HCV nutrients and agents (269–274);
- proanthocyanidin from blueberry leaves inhibits HCV RNA expression, possibly mediated via heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 (275);
- the 17-allylaminogeldanamycin (17-AAG) inhibitor of heat-shock protein 90 (Hsp90) suppresses HCV replication in a dose-dependent manner (276);
- unsymmetrical dialkyl-hydroxynaphthalenyl-benzothiadiazines 2 and 3 inhibit HCV replication (277); and
- honeysuckle extracts (pheophytin a from *Lonicera hypoglauca* Miq.) have potent anti-HCV properties via inhibition of NS3, that are synergistic with INF- α -2a (278).

HCVcc systems have revealed that:

- the cytokine oncostatin M (OSM; a member of the IL-6 family) has an anti-HCV activity that is synergistic with IFN- α (279); and
- the HCV genome encodes single-stranded RNA (ssRNA) ligands of Toll-like receptor 7 (TLR7) that significantly activate innate immunity and induce IFN- α production (280).

Other *in vitro* investigations have elucidated the mechanism of the anti-HCV action of cyclosporin, and illustrated the essential role of the host cyclophilin A (CyPA; 281) and the host SYNCRIP (synaptotagmin-binding, cytoplasmic RNA-interacting protein; 282) in HCV replication.

Development and improvement of therapies and vaccines: Identification of therapeutic targets

Rational drug-design, with regard to ‘Specifically Targeted Anti-viral Therapy for hepatitis C’ (STAT-C), has been made possible via the crystallisation and determination of high-resolution

three-dimensional (3-D) structures of key viral enzymes, often complexed with their substrates, cofactors and/or inhibitors, the activities of which are tested by specific *in vitro* assays (summarised by Locarnini & Bartholomeusz [283]). The yeast two-hybrid system, with HCV core protein used as 'bait' to screen a human liver cDNA expression library, has been used to identify cellular proteins that interact with the HCV core protein (284).

Gondeau *et al.* comprehensively reviewed cellular models in current use for the screening and development of anti-HCV agents, highlighting their utility and productivity. The review listed HCVpp, HCVcc, subgenomic and productive replicons, and primary and immortalised hepatocyte cultures as being used to test more than 55 different anti-viral agents (285). It is asserted that the use of these models will "allow the prediction of the pharmacokinetics of the new chemical entities as well as possible drug interactions and liver toxicity."

In vitro assays have established that cyclophilin B (CyPB), a normal cellular protein, boosts HCV replication by increasing the activity of the HCV polymerase via improvement of its RNA-binding capacity (286). This has important consequences for the design and development of anti-HCV drugs, as a number of HCV inhibitors, such as cyclosporin and related derivatives, function by sequestering cyclophilins (286–289). HT mutational analyses with HCVcc have identified regions of the HCV genome as being suitable candidates for therapeutic and vaccine targets (204).

A new and superior method of screening and identifying innate immunostimulatory molecules, based on primary leukocyte cultures co-cultured with HCV replicon-expressing cells, has been recently announced, which should aid the development of HCV therapeutics (290). A replicon-based HT assay has been developed that permits the screening of inhibitors of HCV genotypes 1a and 1b, and the determination of inhibitor cytotoxicity, within a single well (291). A medium-throughput assay based on flow cytometry, which is able to screen for entry inhibitors that impede the interaction between HCV E2 envelope glycoprotein and host-cell CD81 receptors, is also available (292). A 3-D hollow-fibre culture system, incorporating an immortalised primary human hepatocyte (HuSE/2) cell line, has been created. This system permits the study of blood-borne HCV from patients, as well as the long-term proliferation of the virus and production of infectious virions (293). The developers state that it: "reproduces strain-dependent events reflecting viral dynamics and virus–cell interactions at the early phase of blood-borne HCV infection, ...and allows the development of new anti-HCV strategies specific to various HCV strains."

A recently established reporter cell-line, which utilises secreted alkaline phosphatase (SEAP) as

the reporter molecule, enables much more rapid and sensitive assays of HCV infectivity and replication to be performed, as compared to previous time-consuming and labour-intensive methods (140). It also facilitates the investigation of virus entry and the HT screening of entry inhibitors and other anti-viral agents (294). This method is advantageous, because it allows cell integrity to be maintained, by enabling reporter molecule measurement in the culture medium. It can also be used with any inter-genotypic or intra-genotypic derivative of HCV JFH1, and potentially with other future cell culture-infectious viral isolates. The screening of human siRNA libraries and miRNA expression profiling have identified hundreds of genes that support HCV replication, providing new targets for anti-viral therapy and enabling the *in vitro* testing of the effects on HCV replication of inhibitors of those genes (295–298). In addition, expression profiling has led to the discovery of specific miRNAs that are differentially expressed in HCC/HCV-induced fibrosis/cirrhosis, as well as their target genes (299–303).

The existence of antibodies that cross-neutralise different genotypes of HCV, was demonstrated by using the HCVpp system (119, 120, 122) — a finding that should aid the design of vaccine strategies, and which is permitting the determination of correlates of protection (123).

Development and improvement of therapies and vaccines: Assessment of treatment, vaccine efficacy and toxicity

Clinical research is making progress toward establishing human biomarkers of HCV drug and vaccine efficacy and toxicity, which will lead to safer, quicker and more-effective clinical trials. For example, serum biomarkers of liver fibrosis have already been discovered (304). SNP analysis of human biological samples has characterised particular SNPs that indicate the likelihoods of successful response to IFN therapy, spontaneous viral clearance and progression to fibrosis (305, 306). Microarray profiling of human tissue has provided gene expression signatures for IFN treatment in responders and non-responders, and identified mechanisms of failed response (307–309).

A study performed with cell lines derived from HCV patients, illustrated that expression levels of, and polymorphisms in, the SOCS3 gene, represent important biomarkers for the *a priori* prediction of response to HCV anti-viral therapy (310). Comparative studies of Caucasian and North American Aboriginal populations revealed that ethnicity might influence responses to IFN-alpha (via IL-10 production; 311, 312), which could explain the enhanced propensity of the latter group to clear HCV infection (313). Another new

cell culture method has been developed to model relapse after the end of IFN therapy, which involves the use of IFN-alpha-resistant, genome-length HCV RNA-harboring cells (314). This model has been used to assess alternative anti-HCV agents and has shown that those with a different mode of action to that of IFN-alpha can prevent relapse.

A fully-human modular immune *in vitro* construct ('MIMIC') has been developed, which should serve as a reliable and human-specific *in vitro* test system for proposed HCV vaccines. By using white blood cells from volunteer donors, it involves "optimised PBMC culture systems via recombination of distinct leukocyte components of the immune system, T-cells, B-cells, and dendritic cells (DCs), at ratios similar to those found at sites of *in vivo* lymphocyte activation" (315). Autologous DCs pulsed with test vaccines are introduced to the cultures, and the humoral and cell-mediated immune responses induced by the vaccine candidate can be studied. A 'peripheral tissue equivalent' (PTE) module serves to model events at the vaccination site and/or point of microbial attack, providing data concerning the innate immune response in terms of cytokine production/inflammation and maturation of antigen-presenting cells; similarly, a 'lymphoid tissue equivalent' (LTE) module models adaptive immunity/lymph node events, assessing B-cell and T-cell activities and antibody production. Advantages of the MIMIC system include its capacity to test adjuvants, vaccine components and complete vaccines, and its use to assess the quality of established vaccines. Also, each well of the 96-well plate provided, represents the immune system of a specific individual human being — thus reflecting human biological and immunological diversity across the whole plate. The stated goals of this system are to obviate preclinical, animal-based vaccine tests and to identify optimal human vaccine formulations. Given the performance of this system to date, there is robust evidence that its use will reduce the risk of adverse events in clinical trials, elucidate why some vaccines work in certain populations of people but not in others, and address safety and immunogenicity issues. Furthermore, this method is applicable, not just to vaccines, but also to the immunotoxicological evaluation of other drugs and biologicals.

Mathematical models

Mathematical models have helped to further our understanding of HCV dynamics and clinical trial results in humans (reviewed by Shudo *et al.* [316]). Based on data acquired from people undergoing IFN-alpha treatment, the mechanism of action and efficacy of IFN-alpha were elucidated, along with the dynamics of HCV produc-

tion and clearance (317). Other mathematical models have:

- revealed that both rapid and slow biological processes occur following HCV infection, the knowledge of which has impacted the use of anti-virals in HCV patients (318);
- permitted the physiologically-based pharmacokinetic modelling of putative new drugs, in order to predict their properties in the human body (e.g. 316, 319, 320);
- provided insights into the mode of action of ribavirin (321); and
- generated valuable data concerning the different responses of diverse patient populations to anti-viral therapy (245).

Discussion and Conclusions

This paper, together with the associated paper (18), sought to critically evaluate claims of necessity for the use of chimpanzees in hepatitis C research. This is timely and of high importance, due to the controversial nature of invasive chimpanzee research (which is now practised only in the USA), and the reintroduction of the *Great Ape Protection Act* (GAPA) bill in the US House of Representatives that seeks to end it. This bill has significant consequences, not just for the 1,000 chimpanzees in US laboratories, but also for many millions of people relying on science to provide treatments and cures for hepatitis C and other diseases.

Paper 1 (18) examined the scientific validity of the chimpanzee model. By directly assessing the claims of advocates of chimpanzee HCV research that it made crucial contributions to past progress — claims that have been subject to little critical analysis to date — the chimpanzee model's proposed critical role in future investigations can begin to be gauged. The conclusions of the review were that these assertions were exaggerated and unjustifiable. While chimpanzees have been involved in many areas of HCV research, the contribution of chimpanzee data to the advancement of knowledge and to tangible progress was negligible, and was eclipsed by that of other methods of inquiry. When considered alongside acknowledged and serious scientific caveats of the chimpanzee model of hepatitis C, as well as ethical, economic and practical caveats of chimpanzee use in general, it was concluded that the chimpanzee model in HCV research must now be considered redundant.

This complementary review augments the findings of the first paper, by illustrating how non-chimpanzee methods have contributed to the development of important *in vitro* methods for

studying the HCV life-cycle. While full life-cycle infectious cellular clones represent the long awaited and most comprehensive *in vitro* system for many aspects of HCV study, all the *in vitro* methods employed, including HCV-infected cultured primary and immortalised cells, infectious molecular clones, subgenomic and genomic replicons, and virus-like particles and pseudoparticles, have added greatly to the body of knowledge on the hepatitis C virus and hepatitis C pathology, as well as enhancing progress toward new treatments. Furthermore, this review describes how full life-cycle infectious clones (HCVcc), which were urgently called for by the research community for decades, can provide all the necessary data to facilitate the development and testing of HCV therapies, when supported by clinical, epidemiological, *ex vivo* and *in silico* methods.

It is now possible to investigate the complete HCV life-cycle, from host-cell attachment to release of progeny, immune responses to infection, the roles of host factors, identification of therapeutic targets, testing of new therapies and vaccines, and so on, in a human, and therefore completely relevant, context. While it must be acknowledged that all methods of investigation have inherent imperfections and caveats, including the use of human cultured cells *per se*, and the biological differences between the use of HCV *in vitro* in human cells and the *in vivo* situation in humans, the evidence suggests that the use of human cells *in vitro* is much more relevant to human biology than the use, albeit *in vivo*, of another animal entirely (i.e. the chimpanzee) as a 'model' organism. Notably, while chimpanzee use is declining markedly (in 2008, the NIH funded 220 human hepatitis trials, as compared to just 35 chimpanzee projects, the latter having decreased by 50% over the past 30 years), the use of the various human-cell culture systems in the study of HCV is continuing to produce large amounts of important data, particularly when used alongside other methods.

In summary, there is a very strong argument against any scientific requirement for the use of chimpanzees in hepatitis C research, and an equally strong argument in support of the concentration of research effort in human-specific clinical and *in vitro* technologies. Prohibiting chimpanzee use would accelerate progress by releasing extra funds for more-productive and scientifically-superior alternatives, benefiting the hundreds of millions of human beings infected with, or at risk of being infected by, HCV, as well as for the approximate 1,000 chimpanzees in US laboratories.

Acknowledgements

Jarrold Bailey was the sole author of this manuscript, and was responsible for its conception,

research and preparation. The work herein has not been presented anywhere else prior to this publication. Sincere gratitude is expressed to the New England Anti-Vivisection Society for funding the project, and also to the British Union for the Abolition of Vivisection for its generous contribution. Thanks go to Theodora Capaldo and all the others who offered their time and expertise in reviewing the manuscript during its preparation. There are no conflicts of interest.

Received 09.02.10; received in final form 09.07.10; accepted for publication 14.07.10.

References

1. Gottwein, J.M. & Bukh, J. (2008). Cutting the Gordian knot-development and biological relevance of hepatitis C virus cell culture systems. *Advances in Virus Research* **71**, 51–133.
2. Marcellin, P. (2009). Hepatitis B and hepatitis C in 2009. *Liver International* **29**, Suppl. 1, 1–8.
3. Soriano, V., Madejon, A., Vispo, E., Labarga, P., Garcia-Samaniego, J., Martin-Carbonero, L., Sheldon, J., Bottecchia, M., Tuma, P. & Barreiro, P. (2008). Emerging drugs for hepatitis C. *Expert Opinion on Emerging Drugs* **13**, 1–19.
4. Poynard, T., Bedossa, P. & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* **349**, 825–832.
5. Lauer, G.M. & Walker, B.D. (2001). Hepatitis C virus infection. *New England Journal of Medicine* **345**, 41–52.
6. Walters, K.A. & Katze, M.G. (2009). Using high-throughput genomics to study hepatitis C: What determines the outcome of infection? *Antiviral Research* **81**, 198–208.
7. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W. & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science, New York* **244**, 359–362.
8. NEAVS (2010). *End Chimpanzee Research: Overview — International Bans*. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: <http://www.releasechimps.org/mission/end-chimpanzee-research/country-bans/> (Accessed 19.10.10).
9. Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow, G. (2008). Building an inner sanctuary: Complex PTSD in chimpanzees. *Journal of Trauma Dissociation* **9**, 9–34.
10. Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow, G. (2009). Developmental context effects on bi-cultural post-trauma self repair in chimpanzees. *Developmental Psychology* **45**, 1376–1388.
11. Sauer, U.G. (2000). Reasons for not using primates in research. [German.] *ALTEX* **17**, 217–220.
12. Thew, M. (2002). Are results of primate research worth the suffering it causes? *Nature, London* **418**, 273.
13. Bailey, J. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. *ATLA* **36**,

- 381–428.
14. Bailey, J., Balcombe, J. & Capaldo, T. (2007). *Chimpanzee Research: An Examination of Its Contribution to Biomedical Knowledge and Efficacy in Combating Human Diseases*, 47pp. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: <http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf> (Accessed 19.10.10).
 15. Knight, A. (2007). The poor contribution of chimpanzee experiments to biomedical progress. *Journal of Applied Animal Welfare Science* **10**, 281–308.
 16. de Kok, W. (2002). *Dutch Lab Chimps to be Retired*. Summerville, SC, USA: International Primate Protection League. Available at: <http://www.ippl.org/2002-dutch-chimps.php> (Accessed 09.12.10).
 17. Vermij, P. (2003). Europe's last research chimps to retire. *Nature Medicine* **9**, 981.
 18. Bailey, J. (2010). An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model. *ATLA* **38**, 387–418.
 19. Houghton, M. & Abrignani, S. (2005). Prospects for a vaccine against the hepatitis C virus. *Nature, London* **436**, 961–966.
 20. Forns, X., Bukh, J. & Purcell, R.H. (2002). The challenge of developing a vaccine against hepatitis C virus. *Journal of Hepatology* **37**, 684–695.
 21. Bukh, J., Forns, X., Emerson, S.U. & Purcell, R.H. (2001). Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. *Intervirology* **44**, 132–142.
 22. Bukh, J. (2004). A critical role for the chimpanzee model in the study of hepatitis C. *Hepatology* **39**, 1469–1475.
 23. Elmowalid, G.A., Qiao, M., Jeong, S.-H., Borg, B.B., Baumert, T.F., Sapp, R.K., Hu, Z., Murthy, K. & Liang, T.J. (2007). Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. *Proceedings of the National Academy of Sciences of the USA* **104**, 8427–8432.
 24. Lanford, R.E., Bigger, C., Bassett, S. & Klimpel, G. (2001). The chimpanzee model of hepatitis C virus infections. *ILAR Journal* **42**, 117–126.
 25. Bartenschlager, R. & Lohmann, V. (2001). Novel cell culture systems for the hepatitis C virus. *Antiviral Research* **52**, 1–17.
 26. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L. & Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science, New York* **285**, 110–113.
 27. Brass, V., Moradpour, D. & Blum, H.E. (2007). Hepatitis C virus infection: *In vivo* and *in vitro* models. *Journal of Viral Hepatitis* **14**, Suppl. 1, 64–67.
 28. Lazaro, C.A., Chang, M., Tang, W., Campbell, J., Sullivan, D.G., Gretch, D.R., Corey, L., Coombs, R.W. & Fausto, N. (2007). Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. *American Journal of Pathology* **170**, 478–489.
 29. Gallo, R.C. (1993). *Virus Hunting: Aids, Cancer, and the Human Retrovirus: A Story of Scientific Discovery*, 368pp. New York, NY, USA: Basic Books.
 30. Enders, J.F. & Peebles, T.C. (1954). Propagation in tissue cultures of cytopathogenic agents from patients with measles. *Proceedings of the Society for Experimental Biology & Medicine* **86**, 277–286.
 31. Asselah, T., Benhamou, Y. & Marcellin, P. (2009). Protease and polymerase inhibitors for the treatment of hepatitis C. *Liver International* **29**, Suppl. 1, 57–67.
 32. Duverlie, G. & Wychowski, C. (2007). Cell culture systems for the hepatitis C virus. *World Journal of Gastroenterology* **13**, 2442–2445.
 33. Regnard, M., Lepere, C., Trotard, M., Gripon, P. & Le Seyec, J. (2007). Recent contributions of *in vitro* models to our understanding of hepatitis C virus life cycle. *FEBS Journal* **274**, 4705–4718.
 34. Sheehy, P., Mullan, B., Moreau, I., Kenny-Walsh, E., Shanahan, F., Scallan, M. & Fanning, L.J. (2007). *In vitro* replication models for the hepatitis C virus. *Journal of Viral Hepatitis* **14**, 2–10.
 35. Iacovacci, S., Manzin, A., Barca, S., Sargiacomo, M., Serafino, A., Valli, M.B., Macioce, G., Hassan, H.J., Ponzetto, A., Clementi, M., Peschle, C. & Carloni, G. (1997). Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected *in vitro*. *Hepatology* **26**, 1328–1337.
 36. Iacovacci, S., Sargiacomo, M., Parolini, I., Ponzetto, A., Peschle, C. & Carloni, G. (1993). Replication and multiplication of hepatitis C virus genome in human foetal liver cells. *Research in Virology* **144**, 275–279.
 37. Rumin, S., Berthillon, P., Tanaka, E., Kiyosawa, K., Trabaud, M.A., Bizollon, T., Gouillat, C., Gripon, P., Guguen-Guillouzo, C., Inchauspé, G. & Trepo, C. (1999). Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected *in vitro*. *Journal of General Virology* **80**, 3007–3018.
 38. Fournier, C., Sureau, C., Coste, J., Ducos, J., Pageaux, G., Larrey, D., Domergue, J. & Maurel, P. (1998). *In vitro* infection of adult normal human hepatocytes in primary culture by hepatitis C virus. *Journal of General Virology* **79**, 2367–2374.
 39. Cribier, B., Schmitt, C., Bingen, A., Kirn, A. & Keller, F. (1995). *In vitro* infection of peripheral blood mononuclear cells by hepatitis C virus. *Journal of General Virology* **76**, 2485–2491.
 40. Shimizu, Y.K., Iwamoto, A., Hijikata, M., Purcell, R.H. & Yoshikura, H. (1992). Evidence for *in vitro* replication of hepatitis C virus genome in a human T-cell line. *Proceedings of the National Academy of Sciences of the USA* **89**, 5477–5481.
 41. Kato, N., Nakazawa, T., Mizutani, T. & Shimotohno, K. (1995). Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. *Biochemical & Biophysical Research Communications* **206**, 863–869.
 42. Shimizu, Y.K., Purcell, R.H. & Yoshikura, H. (1993). Correlation between the infectivity of hepatitis C virus *in vivo* and its infectivity *in vitro*. *Proceedings of the National Academy of Sciences of the USA* **90**, 6037–6041.
 43. Nakajima, N., Hijikata, M., Yoshikura, H. & Shimizu, Y.K. (1996). Characterization of long-term cultures of hepatitis C virus. *Journal of Virology* **70**, 3325–3329.
 44. Seipp, S., Mueller, H.M., Pfaff, E., Stremmel, W., Theilmann, L. & Goeser, T. (1997). Establishment of persistent hepatitis C virus infection and replication *in vitro*. *Journal of General Virology* **78**,

- 2467–2476.
45. Kato, N., Ikeda, M., Mizutani, T., Sugiyama, K., Noguchi, M., Hirohashi, S. & Shimotohno, K. (1996). Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. *Japanese Journal of Cancer Research* **87**, 787–792.
 46. Ito, T., Mukaigawa, J., Zuo, J., Hirabayashi, Y., Mitamura, K. & Yasui, K. (1996). Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. *Journal of General Virology* **77**, 1043–1054.
 47. Muller, H.M., Pfaff, E., Goeser, T., Kallinowski, B., Solbach, C. & Theilmann, L. (1993). Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. *Journal of General Virology* **74**, 669–676.
 48. Molina, S., Castet, V., Fournier-Wirth, C., Pichard-Garcia, L., Avner, R., Harats, D., Roitelman, J., Barbaras, R., Graber, P., Ghersa, P., Smolarsky, M., Funaro, A., Malavasi, F., Larrey, D., Coste, J., Fabre, J.M., Sa-Cunha, A. & Maurel, P. (2007). The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. *Journal of Hepatology* **46**, 411–419.
 49. Sung, V.M., Shimodaira, S., Doughty, A.L., Picchio, G.R., Can, H., Yen, T.S., Lindsay, K.L., Levine, A.M. & Lai, M.M. (2003). Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus *in vivo* and *in vitro*: The apoptotic effects of virus infection. *Journal of Virology* **77**, 2134–2146.
 50. Gale, M.J. & Beard, M.R. (2001). Molecular clones of hepatitis C virus: Applications to animal models. *ILAR Journal* **42**, 139–151.
 51. Kolykhalov, A.A., Agapov, E.V., Blight, K.J., Mihalik, K., Feinstone, S.M. & Rice, C.M. (1997). Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science, New York* **277**, 570–574.
 52. Yanagi, M., Purcell, R.H., Emerson, S.U. & Bukh, J. (1997). Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. *Proceedings of the National Academy of Sciences of the USA* **94**, 8738–8743.
 53. Moormann, R.J., van Gennip, H.G., Miedema, G.K., Hulst, M.M. & van Rijn, P.A. (1996). Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. *Journal of Virology* **70**, 763–770.
 54. Bartenschlager, R. (2006). Hepatitis C virus molecular clones: From cDNA to infectious virus particles in cell culture. *Current Opinion in Microbiology* **9**, 416–422.
 55. Higashi, Y., Kakumu, S., Yoshioka, K., Wakita, T., Mizokami, M., Ohba, K., Ito, Y., Ishikawa, T., Takayanagi, M. & Nagai, Y. (1993). Dynamics of genome change in the E2/NS1 region of hepatitis C virus *in vivo*. *Virology* **197**, 659–668.
 56. Yagi, S., Mori, K., Tanaka, E., Matsumoto, A., Sunaga, F., Kiyosawa, K. & Yamaguchi, K. (2005). Identification of novel HCV subgenome replicating persistently in chronic active hepatitis C patients. *Journal of Medical Virology* **77**, 399–413.
 57. Yoo, B.J., Selby, M.J., Choe, J., Suh, B.S., Choi, S.H., Joh, J.S., Nuovo, G.J., Lee, H.S., Houghton, M. & Han, J.H. (1995). Transfection of a differentiated human hepatoma cell line (Huh7) with *in vitro*-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. *Journal of Virology* **69**, 32–38.
 58. Dash, S., Halim, A.B., Tsuji, H., Hiramatsu, N. & Gerber, M.A. (1997). Transfection of HepG2 cells with infectious hepatitis C virus genome. *American Journal of Pathology* **151**, 363–373.
 59. Bartenschlager, R. & Sparacio, S. (2007). Hepatitis C virus molecular clones and their replication capacity *in vivo* and in cell culture. *Virus Research* **127**, 195–207.
 60. Myung, J., Khalap, N., Kalkeri, G., Garry, R. & Dash, S. (2001). Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone. *Journal of Virological Methods* **94**, 55–67.
 61. Lim, S.P., Soo, H.M., Tan, Y.H., Brenner, S., Horstmann, H., MacKenzie, J.M., Ng, M.L., Lim, S.G. & Hong, W. (2002). Inducible system in human hepatoma cell lines for hepatitis C virus production. *Virology* **303**, 79–99.
 62. Moradpour, D., Wakita, T., Wands, J.R. & Blum, H.E. (1998). Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. *Biochemical & Biophysical Research Communications* **246**, 920–924.
 63. Moradpour, D., Kary, P., Rice, C.M. & Blum, H.E. (1998). Continuous human cell lines inducibly expressing hepatitis C virus structural and non-structural proteins. *Hepatology* **28**, 192–201.
 64. Qi, Z.T., Kalkeri, G., Hanible, J., Prabhu, R., Bastian, F., Garry, R.F. & Dash, S. (2003). Stem-loop structures II–IV of the 5′ untranslated sequences are required for the expression of the full-length hepatitis C virus genome. *Archives of Virology* **148**, 449–467.
 65. Kalkeri, G., Khalap, N., Akhter, S., Garry, R.F., Fermin, C.D. & Dash, S. (2001). Hepatitis C viral proteins affect cell viability and membrane permeability. *Experimental & Molecular Pathology* **71**, 194–208.
 66. Huang, Y., Uchiyama, Y., Fujimura, T., Kanamori, H., Doi, T., Takamizawa, A., Hamakubo, T. & Kodama, T. (2001). A human hepatoma cell line expressing hepatitis C virus nonstructural proteins tightly regulated by tetracycline. *Biochemical & Biophysical Research Communications* **281**, 732–740.
 67. Heim, M.H., Moradpour, D. & Blum, H.E. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. *Journal of Virology* **73**, 8469–8475.
 68. Prabhu, R., Joshi, V., Garry, R.F., Bastian, F., Haque, S., Regenstein, F., Thung, S. & Dash, S. (2004). Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. *Experimental & Molecular Pathology* **76**, 242–252.
 69. Chung, R.T., He, W., Saquib, A., Contreras, A.M., Xavier, R.J., Chawla, A., Wang, T.C. & Schmidt, E.V. (2001). Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. *Proceedings of the National Academy of Sciences of the USA* **98**, 9847–9852.
 70. Harada, T., Kim, D.W., Sagawa, K., Suzuki, T., Takahashi, K., Saito, I., Matsuura, Y. & Miyamura, T. (1995). Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by

- transfection of viral cDNA. *Journal of General Virology* **76**, 1215–1221.
71. Schmidt-Mende, J., Bieck, E., Hugle, T., Penin, F., Rice, C.M., Blum, H.E. & Moradpour, D. (2001). Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. *Journal of Biological Chemistry* **276**, 44,052–44,063.
 72. Wolk, B., Sansonno, D., Krausslich, H.G., Dammacco, F., Rice, C.M., Blum, H.E. & Moradpour, D. (2000). Subcellular localization, stability, and *trans*-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. *Journal of Virology* **74**, 2293–2304.
 73. Bartenschlager, R., Frese, M. & Pietschmann, T. (2004). Novel insights into hepatitis C virus replication and persistence. *Advances in Virus Research* **63**, 71–180.
 74. Lindenbach, B.D. & Rice, C.M. (2005). Unravelling hepatitis C virus replication from genome to function. *Nature, London* **436**, 933–938.
 75. De Francesco, R. & Migliaccio, G. (2005). Challenges and successes in developing new therapies for hepatitis C. *Nature, London* **436**, 953–960.
 76. Khromykh, A.A. & Westaway, E.G. (1997). Subgenomic replicons of the flavivirus Kunjin: Construction and applications. *Journal of Virology* **71**, 1497–1505.
 77. Behrens, S.E., Grassmann, C.W., Thiel, H.J., Meyers, G. & Tautz, N. (1998). Characterization of an autonomous subgenomic pestivirus RNA replicon. *Journal of Virology* **72**, 2364–2372.
 78. Kaplan, G. & Racaniello, V.R. (1988). Construction and characterization of poliovirus subgenomic replicons. *Journal of Virology* **62**, 1687–1696.
 79. Blight, K.J., Kolykhalov, A.A. & Rice, C.M. (2000). Efficient initiation of HCV RNA replication in cell culture. *Science, New York* **290**, 1972–1974.
 80. Lohmann, V., Korner, F., Dobierzewska, A. & Bartenschlager, R. (2001). Mutations in hepatitis C virus RNAs conferring cell culture adaptation. *Journal of Virology* **75**, 1437–1449.
 81. Blight, K.J., McKeating, J.A., Marcotrigiano, J. & Rice, C.M. (2003). Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *Journal of Virology* **77**, 3181–3190.
 82. Yi, M. & Lemon, S.M. (2004). Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. *Journal of Virology* **78**, 7904–7915.
 83. Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M. & Wakita, T. (2003). Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. *Gastroenterology* **125**, 1808–1817.
 84. Lohmann, V., Hoffmann, S., Herian, U., Penin, F. & Bartenschlager, R. (2003). Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. *Journal of Virology* **77**, 3007–3019.
 85. Blight, K.J., McKeating, J.A. & Rice, C.M. (2002). Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *Journal of Virology* **76**, 13,001–13,014.
 86. Friebe, P., Boudet, J., Simorre, J.P. & Bartenschlager, R. (2005). Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. *Journal of Virology* **79**, 380–392.
 87. Yi, M., Villanueva, R.A., Thomas, D.L., Wakita, T. & Lemon, S.M. (2006). Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proceedings of the National Academy of Sciences of the USA* **103**, 2310–2315.
 88. Adair, R., Patel, A.H., Corless, L., Griffin, S., Rowlands, D. & McCormick, C.J. (2009). Expression of HCV structural proteins in *trans* facilitates encapsidation and transmission of HCV subgenomic RNA. *Journal of General Virology* **90**, 833–842.
 89. Ishii, K., Murakami, K., Hmwe, S.S., Zhang, B., Li, J., Shirakura, M., Morikawa, K., Suzuki, R., Miyamura, T., Wakita, T. & Suzuki, T. (2008). *Trans*-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. *Biochemical & Biophysical Research Communications* **371**, 446–450.
 90. Steinmann, E., Brohm, C., Kallis, S., Bartenschlager, R. & Pietschmann, T. (2008). Efficient *trans*-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. *Journal of Virology* **82**, 7034–7046.
 91. Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R.M., Acali, S., Filocamo, G., Traboni, C., Nicosia, A., Cortese, R. & Vitelli, A. (2002). The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *EMBO Journal* **21**, 5017–5025.
 92. Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A.J., Houghton, M., Rosa, D., Grandi, G. & Abrignani, S. (1998). Binding of hepatitis C virus to CD81. *Science, New York* **282**, 938–941.
 93. Flint, M., Thomas, J.M., Maidens, C.M., Shotton, C., Levy, S., Barclay, W.S. & McKeating, J.A. (1999). Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. *Journal of Virology* **73**, 6782–6790.
 94. Baumert, T.F., Ito, S., Wong, D.T. & Liang, T.J. (1998). Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. *Journal of Virology* **72**, 3827–3836.
 95. Baumert, T.F., Wellnitz, S., Aono, S., Satoh, J., Herion, D., Tilman Gerlach, J., Pape, G.R., Lau, J.Y., Hoofnagle, J.H., Blum, H.E. & Liang, T.J. (2000). Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. *Hepatology* **32**, 610–617.
 96. Owsianka, A., Clayton, R.F., Loomis-Price, L.D., McKeating, J.A. & Patel, A.H. (2001). Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. *Journal of General Virology* **82**, 1877–1883.
 97. Triyatni, M., Vergalla, J., Davis, A.R., Hadlock, K.G., Fount, S.K. & Liang, T.J. (2002). Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. *Virology* **298**, 124–132.
 98. Triyatni, M., Saunier, B., Maruvada, P., Davis, A.R., Ulianich, L., Heller, T., Patel, A., Kohn, L.D. & Liang, T.J. (2002). Interaction of hepatitis C virus-like particles and cells: A model system for studying viral binding and entry. *Journal of Virology* **76**, 9335–9344.
 99. Wellnitz, S., Klumpp, B., Barth, H., Ito, S., Depla, E., Dubuisson, J., Blum, H.E. & Baumert, T.F. (2002). Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined

- human cell lines. *Journal of Virology* **76**, 1181–1193.
100. Agnello, V., Abel, G., Elfahal, M., Knight, G.B. & Zhang, Q.X. (1999). Hepatitis C virus and other *Flaviviridae* viruses enter cells via low density lipoprotein receptor. *Proceedings of the National Academy of Sciences of the USA* **96**, 12,766–12,771.
 101. Barth, H., Schafer, C., Adah, M.I., Zhang, F., Linhardt, R.J., Toyoda, H., Kinoshita-Toyoda, A., Toida, T., Van Kuppevelt, T.H., Depla, E., Von Weizsacker, F., Blum, H.E. & Baumert, T.F. (2003). Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. *Journal of Biological Chemistry* **278**, 41,003–41,012.
 102. Barth, H., Schnober, E.K., Zhang, F., Linhardt, R.J., Depla, E., Boson, B., Cosset, F.L., Patel, A.H., Blum, H.E. & Baumert, T.F. (2006). Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. *Journal of Virology* **80**, 10,579–10,590.
 103. Evans, M.J., von Hahn, T., Tscherne, D.M., Syder, A.J., Panis, M., Wolk, B., Hatzioannou, T., McKeating, J.A., Bieniasz, P.D. & Rice, C.M. (2007). Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature, London* **446**, 801–805.
 104. Barth, H., Ulsenheimer, A., Pape, G.R., Diepolder, H.M., Hoffmann, M., Neumann-Haefelin, C., Thimme, R., Henneke, P., Klein, R., Paranhos-Baccala, G., Depla, E., Liang, T.J., Blum, H.E. & Baumert, T.F. (2005). Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. *Blood* **105**, 3605–3614.
 105. Fang, X., Zeisel, M.B., Wilpert, J., Gissler, B., Thimme, R., Kreutz, C., Maiwald, T., Timmer, J., Kern, W.V., Donauer, J., Geyer, M., Walz, G., Depla, E., von Weizsacker, F., Blum, H.E. & Baumert, T.F. (2006). Host cell responses induced by hepatitis C virus binding. *Hepatology* **43**, 1326–1336.
 106. Bartosch, B., Dubuisson, J. & Cosset, F.L. (2003). Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. *Journal of Experimental Medicine* **197**, 633–642.
 107. Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C.M. & McKeating, J.A. (2003). Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proceedings of the National Academy of Sciences of the USA* **100**, 7271–7276.
 108. Matsuura, Y., Tani, H., Suzuki, K., Kimura-Someya, T., Suzuki, R., Aizaki, H., Ishii, K., Moriishi, K., Robison, C.S., Whitt, M.A. & Miyamura, T. (2001). Characterization of pseudotype VSV possessing HCV envelope proteins. *Virology* **286**, 263–275.
 109. Barth, H., Liang, T.J. & Baumert, T.F. (2006). Hepatitis C virus entry: Molecular biology and clinical implications. *Hepatology* **44**, 527–535.
 110. Cocquerel, L., Voisset, C. & Dubuisson, J. (2006). Hepatitis C virus entry: Potential receptors and their biological functions. *Journal of General Virology* **87**, 1075–1084.
 111. Bartosch, B. & Cosset, F.L. (2006). Cell entry of hepatitis C virus. *Virology* **348**, 1–12.
 112. Zeisel, M.B. & Baumert, T.F. (2006). Production of infectious hepatitis C virus in tissue culture: A breakthrough for basic and applied research. *Journal of Hepatology* **44**, 436–439.
 113. Connelly, M.A. & Williams, D.L. (2004). SR-BI and HDL cholesteryl ester metabolism. *Endocrine Research* **30**, 697–703.
 114. Bartosch, B., Vitelli, A., Granier, C., Goujon, C., Dubuisson, J., Pascale, S., Scarselli, E., Cortese, R., Nicosia, A. & Cosset, F.L. (2003). Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. *Journal of Biological Chemistry* **278**, 41,624–41,630.
 115. von Hahn, T., Lindenbach, B.D., Boullier, A., Quehenberger, O., Paulson, M., Rice, C.M. & McKeating, J.A. (2006). Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. *Hepatology* **43**, 932–942.
 116. Voisset, C., Callens, N., Blanchard, E., Op de Beeck, A., Dubuisson, J. & Vu-Dac, N. (2005). High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. *Journal of Biological Chemistry* **280**, 7793–7799.
 117. Voisset, C., Op de Beeck, A., Horellou, P., Dreux, M., Gustot, T., Duverlie, G., Cosset, F.L., Vu-Dac, N. & Dubuisson, J. (2006). High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. *Journal of General Virology* **87**, 2577–2581.
 118. Bartosch, B., Verney, G., Dreux, M., Donot, P., Morice, Y., Penin, F., Pawlotsky, J.M., Lavillette, D. & Cosset, F.L. (2005). An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. *Journal of Virology* **79**, 8217–8229.
 119. Meunier, J.C., Engle, R.E., Faulk, K., Zhao, M., Bartosch, B., Alter, H., Emerson, S.U., Cosset, F.L., Purcell, R.H. & Bukh, J. (2005). Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. *Proceedings of the National Academy of Sciences of the USA* **102**, 4560–4565.
 120. Bartosch, B., Bukh, J., Meunier, J.C., Granier, C., Engle, R.E., Blackwelder, W.C., Emerson, S.U., Cosset, F.L. & Purcell, R.H. (2003). *In vitro* assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. *Proceedings of the National Academy of Sciences of the USA* **100**, 14,199–14,204.
 121. Tanaka, T., Kato, N., Cho, M.J. & Shimotohno, K. (1995). A novel sequence found at the 3' terminus of hepatitis C virus genome. *Biochemical & Biophysical Research Communications* **215**, 744–749.
 122. Logvinoff, C., Major, M.E., Oldach, D., Heyward, S., Talal, A., Balfe, P., Feinstone, S.M., Alter, H., Rice, C.M. & McKeating, J.A. (2004). Neutralizing antibody response during acute and chronic hepatitis C virus infection. *Proceedings of the National Academy of Sciences of the USA* **101**, 10,149–10,154.
 123. Lavillette, D., Morice, Y., Germanidis, G., Donot, P., Soulier, A., Pagkalos, E., Sakellariou, G., Intrator, L., Bartosch, B., Pawlotsky, J.M. & Cosset, F.L. (2005). Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. *Journal of Virology* **79**, 6023–6034.
 124. Johansson, D.X., Voisset, C., Tarr, A.W., Aung, M.,

- Ball, J.K., Dubuisson, J. & Persson, M.A. (2007). Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. *Proceedings of the National Academy of Sciences of the USA* **104**, 16,269–16,274.
125. Zhang, K., Tan, W.J., Deng, Y., Li, J., Wu, X.B. & Ruan, L. (2008). Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays. [Chinese.] *Bing Du Xue Bao* **24**, 287–294.
126. Flint, M., Maidens, C., Loomis-Price, L.D., Shotton, C., Dubuisson, J., Monk, P., Higginbottom, A., Levy, S. & McKeating, J.A. (1999). Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. *Journal of Virology* **73**, 6235–6244.
127. Zhang, J., Randall, G., Higginbottom, A., Monk, P., Rice, C.M. & McKeating, J.A. (2004). CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. *Journal of Virology* **78**, 1448–1455.
128. Cormier, E.G., Tsamis, F., Kajumo, F., Durso, R.J., Gardner, J.P. & Dragic, T. (2004). CD81 is an entry coreceptor for hepatitis C virus. *Proceedings of the National Academy of Sciences of the USA* **101**, 7270–7274.
129. Op de Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Fong, S., Cosset, F.L. & Dubuisson, J. (2004). Characterization of functional hepatitis C virus envelope glycoproteins. *Journal of Virology* **78**, 2994–3002.
130. Blanchard, E., Belouzard, S., Goueslain, L., Wakita, T., Dubuisson, J., Wychowski, C. & Rouille, Y. (2006). Hepatitis C virus entry depends on clathrin-mediated endocytosis. *Journal of Virology* **80**, 6964–6972.
131. Meertens, L., Bertaux, C. & Dragic, T. (2006). Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. *Journal of Virology* **80**, 11,571–11,578.
132. Codran, A., Royer, C., Jaeck, D., Bastien-Valle, M., Baumert, T.F., Kieny, M.P., Pereira, C.A. & Martin, J.P. (2006). Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. *Journal of General Virology* **87**, 2583–2593.
133. Lozach, P.Y., Lortat-Jacob, H., de Lacroix de Lavalette, A., Staropoli, I., Fong, S., Amara, A., Houles, C., Fieschi, F., Schwartz, O., Virelizier, J.L., Arenzana-Seisdedos, F. & Altmeyer, R. (2003). DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. *Journal of Biological Chemistry* **278**, 20,358–20,366.
134. Gardner, J.P., Durso, R.J., Arrigale, R.R., Donovan, G.P., Maddon, P.J., Dragic, T. & Olson, W.C. (2003). L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. *Proceedings of the National Academy of Sciences of the USA* **100**, 4498–4503.
135. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.G., Mizokami, M., Bartenschlager, R. & Liang, T.J. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nature Medicine* **11**, 791–796.
136. Kato, T., Furusaka, A., Miyamoto, M., Date, T., Yasui, K., Hiramoto, J., Nagayama, K., Tanaka, T. & Wakita, T. (2001). Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. *Journal of Medical Virology* **64**, 334–339.
137. Kato, T., Date, T., Miyamoto, M., Zhao, Z., Mizokami, M. & Wakita, T. (2005). Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. *Journal of Virology* **79**, 592–596.
138. Date, T., Kato, T., Miyamoto, M., Zhao, Z., Yasui, K., Mizokami, M. & Wakita, T. (2004). Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. *Journal of Biological Chemistry* **279**, 22,371–22,376.
139. Bartenschlager, R. & Pietschmann, T. (2005). Efficient hepatitis C virus cell culture system: What a difference the host cell makes. *Proceedings of the National Academy of Sciences of the USA* **102**, 9739–9740.
140. Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A. & Rice, C.M. (2005). Complete replication of hepatitis C virus in cell culture. *Science, New York* **309**, 623–626.
141. Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D.R., Wieland, S.F., Uprichard, S.L., Wakita, T. & Chisari, F.V. (2005). Robust hepatitis C virus infection *in vitro*. *Proceedings of the National Academy of Sciences of the USA* **102**, 9294–9299.
142. Pietschmann, T., Kaul, A., Koutsoudakis, G., Shavinskaya, A., Kallis, S., Steinmann, E., Abid, K., Negro, F., Dreux, M., Cosset, F.L. & Bartenschlager, R. (2006). Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proceedings of the National Academy of Sciences of the USA* **103**, 7408–7413.
143. Yi, M., Ma, Y., Yates, J. & Lemon, S.M. (2007). Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. *Journal of Virology* **81**, 629–638.
144. Lanford, R.E., Guerra, B. & Lee, H. (2006). Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain. *Virology* **355**, 192–202.
145. Graham, D.J., Stahlhut, M., Flores, O., Olsen, D.B., Hazuda, D.J., Lafemina, R.L. & Ludmerer, S.W. (2006). A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background. *Antiviral Research* **69**, 24–30.
146. Binder, M., Quinkert, D., Bochkarova, O., Klein, R., Kezmic, N., Bartenschlager, R. & Lohmann, V. (2007). Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. *Journal of Virology* **81**, 5270–5283.
147. Bungyoku, Y., Shoji, I., Makine, T., Adachi, T., Hayashida, K., Nagano-Fujii, M., Ide, Y.H., Deng, L. & Hotta, H. (2009). Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. *Journal of General Virology* **90**, 1681–1691.
148. Scheel, T.K., Gottwein, J.M., Jensen, T.B., Prentoe, J.C., Hoegh, A.M., Alter, H.J., Eugen-Olsen, J. & Bukh, J. (2008). Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a

- and evidence for cross-genotype neutralization. *Proceedings of the National Academy of Sciences of the USA* **105**, 997–1002.
149. Kato, T., Matsumura, T., Heller, T., Saito, S., Sapp, R.K., Murthy, K., Wakita, T. & Liang, T.J. (2007). Production of infectious hepatitis C virus of various genotypes in cell cultures. *Journal of Virology* **81**, 4405–4411.
 150. Grove, J., Huby, T., Stamataki, Z., Vanwolleghem, T., Meuleman, P., Farquhar, M., Schwarz, A., Moreau, M., Owen, J.S., Leroux-Roels, G., Balfe, P. & McKeating, J.A. (2007). Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. *Journal of Virology* **81**, 3162–3169.
 151. Koutsoudakis, G., Herrmann, E., Kallis, S., Bartschlag, R. & Pietschmann, T. (2007). The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. *Journal of Virology* **81**, 588–598.
 152. Akazawa, D., Date, T., Morikawa, K., Murayama, A., Miyamoto, M., Kaga, M., Barth, H., Baumert, T.F., Dubuisson, J. & Wakita, T. (2007). CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. *Journal of Virology* **81**, 5036–5045.
 153. Kapadia, S.B., Barth, H., Baumert, T., McKeating, J.A. & Chisari, F.V. (2007). Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. *Journal of Virology* **81**, 374–383.
 154. Catanese, M.T., Graziani, R., von Hahn, T., Moreau, M., Huby, T., Paonessa, G., Santini, C., Luzzago, A., Rice, C.M., Cortese, R., Vitelli, A. & Nicosia, A. (2007). High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. *Journal of Virology* **81**, 8063–8071.
 155. Meunier, J.-C., Russell, R.S., Engle, R.E., Faulk, K.N., Purcell, R.H. & Emerson, S.U. (2008). Apolipoprotein c1 association with hepatitis C virus. *Journal of Virology* **82**, 9647–9656.
 156. Berger, K.L., Cooper, J.D., Heaton, N.S., Yoon, R., Oakland, T.E., Jordan, T.X., Mateu, G., Grakoui, A. & Randall, G. (2009). Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. *Proceedings of the National Academy of Sciences of the USA* **106**, 7577–7582.
 157. Seeff, L.B. (2009). The history of the “natural history” of hepatitis C (1968–2009). *Liver International* **29**, Suppl. 1, 89–99.
 158. Maillard, P., Krawczynski, K., Nitkiewicz, J., Bronnert, C., Sidorkiewicz, M., Gounon, P., Dubuisson, J., Faure, G., Crainic, R. & Budkowska, A. (2001). Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. *Journal of Virology* **75**, 8240–8250.
 159. Petit, M.A., Lievre, M., Peyrol, S., De Sequeira, S., Berthillon, P., Ruigrok, R.W. & Treppe, C. (2005). Enveloped particles in the serum of chronic hepatitis C patients. *Virology* **336**, 144–153.
 160. Roingeard, P., Hourieux, C., Blanchard, E., Brand, D. & Ait-Goughoulte, M. (2004). Hepatitis C virus ultrastructure and morphogenesis. *Biology of the Cell* **96**, 103–108.
 161. Andre, P., Perlemuter, G., Budkowska, A., Brechot, C. & Lotteau, V. (2005). Hepatitis C virus particles and lipoprotein metabolism. *Seminars in Liver Disease* **25**, 93–104.
 162. Kaito, M., Watanabe, S., Tsukiyama-Kohara, K., Yamaguchi, K., Kobayashi, Y., Konishi, M., Yokoi, M., Ishida, S., Suzuki, S. & Kohara, M. (1994). Hepatitis C virus particle detected by immunoelectron microscopic study. *Journal of General Virology* **75**, 1755–1760.
 163. Prince, A.M., Huima-Byron, T., Parker, T.S. & Levine, D.M. (1996). Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. *Journal of Viral Hepatitis* **3**, 11–17.
 164. Diedrich, G. (2006). How does hepatitis C virus enter cells? *The FEBS Journal* **273**, 3871–3885.
 165. Thomssen, R., Bonk, S. & Thiele, A. (1993). Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. *Medical Microbiology & Immunology* **182**, 329–334.
 166. Thomssen, R., Bonk, S., Propfe, C., Heermann, K.H., Kochel, H.G. & Uy, A. (1992). Association of hepatitis C virus in human sera with beta-lipoprotein. *Medical Microbiology & Immunology* **181**, 293–300.
 167. Miyamoto, H., Okamoto, H., Sato, K., Tanaka, T. & Mishiro, S. (1992). Extraordinarily low density of hepatitis C virus estimated by sucrose density gradient centrifugation and the polymerase chain reaction. *Journal of General Virology* **73**, 715–718.
 168. Kono, Y., Hayashida, K., Tanaka, H., Ishibashi, H. & Harada, M. (2003). High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus. *Journal of Medical Virology* **70**, 42–48.
 169. Nielsen, S.U., Bassendine, M.F., Burt, A.D., Martin, C., Pumechockchai, W. & Toms, G.L. (2006). Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. *Journal of Virology* **80**, 2418–2428.
 170. Schettler, V., Monazahian, M., Wieland, E., Ramadori, G., Grunewald, R.W., Thomssen, R. & Muller, G.A. (2001). Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. *European Journal of Clinical Investigation* **31**, 154–155.
 171. Hijikata, M., Shimizu, Y.K., Kato, H., Iwamoto, A., Shih, J.W., Alter, H.J., Purcell, R.H. & Yoshikura, H. (1993). Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. *Journal of Virology* **67**, 1953–1958.
 172. Bradley, D., McCaustland, K., Krawczynski, K., Spelbring, J., Humphrey, C. & Cook, E.H. (1991). Hepatitis C virus: Buoyant density of the factor VIII-derived isolate in sucrose. *Journal of Medical Virology* **34**, 206–208.
 173. Trestart, A., Bacq, Y., Buzelay, L., Dubois, F., Barin, F., Goudeau, A. & Roingeard, P. (1998). Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. *Archives of Virology* **143**, 2241–2245.
 174. Andre, P., Komurian-Pradel, F., Deforges, S., Perret, M., Berland, J.L., Sodayer, M., Pol, S., Brechot, C., Paranhos-Baccala, G. & Lotteau, V. (2002). Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. *Journal of Virology* **76**, 6919–6928.
 175. Huang, H., Sun, F., Owen, D.M., Li, W., Chen, Y.,

- Gale, M.J. & Ye, J. (2007). Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. *Proceedings of the National Academy of Sciences of the USA* **104**, 5848–5853.
176. Suzuki, T., Masaki, T. & Aizaki, H. (2008). Involvement of nonstructural protein 5A and lipids on production of hepatitis C virus particles. [Japanese.] *Uirusu* **58**, 199–205.
177. Casiraghi, M.A., De Paschale, M., Romano, L., Biffi, R., Assi, A., Binelli, G. & Zanetti, A.R. (2004). Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. *Hepatology* **39**, 90–96.
178. Meyer, M.F., Lehmann, M., Cornberg, M., Wiegand, J., Manns, M.P., Klade, C. & Wedemeyer, H. (2007). Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. *Virology Journal* **4**, 58.
179. Cox, A.L., Mosbruger, T., Lauer, G.M., Pardoll, D., Thomas, D.L. & Ray, S.C. (2005). Comprehensive analyses of CD8⁺ T cell responses during longitudinal study of acute human hepatitis C. *Hepatology* **42**, 104–112.
180. Urbani, S., Amadei, B., Fiscaro, P., Tola, D., Orlandini, A., Sacchelli, L., Mori, C., Missale, G. & Ferrari, C. (2006). Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. *Hepatology* **44**, 126–139.
181. Kaplan, D.E., Sugimoto, K., Newton, K., Valiga, M.E., Ikeda, F., Aytaman, A., Nunes, F.A., Lucey, M.R., Vance, B.A., Vonderheide, R.H., Reddy, K.R., McKeating, J.A. & Chang, K.M. (2007). Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. *Gastroenterology* **132**, 654–666.
182. Timm, J., Lauer, G.M., Kavanagh, D.G., Sheridan, I., Kim, A.Y., Lucas, M., Pillay, T., Ouchi, K., Reyor, L.L., Schulze zur Wiesch, J., Gandhi, R.T., Chung, R.T., Bhardwaj, N., Klenerman, P., Walker, B.D. & Allen, T.M. (2004). CD8 epitope escape and reversion in acute HCV infection. *Journal of Experimental Medicine* **200**, 1593–1604.
183. Neumann-Haefelin, C., McKiernan, S., Ward, S., Viazov, S., Spangenberg, H.C., Killinger, T., Baumert, T.F., Nazarova, N., Sheridan, I., Pybus, O., von Weizsacker, F., Roggendorf, M., Kelleher, D., Klenerman, P., Blum, H.E. & Thimme, R. (2006). Dominant influence of an HLA-B27 restricted CD8⁺ T cell response in mediating HCV clearance and evolution. *Hepatology* **43**, 563–572.
184. Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J.C., Strazzera, A., Chien, D.Y., Munoz, S.J., Balestrieri, A., Purcell, R.H. & Alter, H.J. (2000). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science, New York* **288**, 339–344.
185. Rehmann, B., Chang, K.M., McHutchinson, J., Kokka, R., Houghton, M., Rice, C.M. & Chisari, F.V. (1996). Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. *Journal of Virology* **70**, 7092–7102.
186. Nelson, D.R., Marousis, C.G., Davis, G.L., Rice, C.M., Wong, J., Houghton, M. & Lau, J.Y. (1997). The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. *Journal of Immunology* **158**, 1473–1481.
187. Ray, S.C., Wang, Y.M., Laeyendecker, O., Ticehurst, J.R., Villano, S.A. & Thomas, D.L. (1999). Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. *Journal of Virology* **73**, 2938–2946.
188. Taylor, D.R., Shi, S.T., Romano, P.R., Barber, G.N. & Lai, M.M. (1999). Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. *Science, New York* **285**, 107–110.
189. Gale, M.J.J., Korth, M.J., Tang, N.M., Tan, S.L., Hopkins, D.A., Dever, T.E., Polyak, S.J., Gretch, D.R. & Katze, M.G. (1997). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. *Virology* **230**, 217–227.
190. Chapel, H.M., Christie, J.M., Peach, V. & Chapman, R.W. (2001). Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. *Clinical Immunology* **99**, 320–324.
191. Lai, M.E., Mazzoleni, A.P., Argioli, F., De Virgili, S., Balestrieri, A., Purcell, R.H., Cao, A. & Farci, P. (1994). Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. *Lancet* **343**, 388–390.
192. Bjoro, K., Froland, S.S., Yun, Z., Samdal, H.H. & Haaland, T. (1994). Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. *New England Journal of Medicine* **331**, 1607–1611.
193. Post, J.J., Pan, Y., Freeman, A.J., Harvey, C.E., White, P.A., Palladinetti, P., Haber, P.S., Marinos, G., Levy, M.H., Kaldor, J.M., Dolan, K.A., Ffrench, R.A., Lloyd, A.R. & Rawlinson, W.D. (2004). Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. *Journal of Infectious Diseases* **189**, 1846–1855.
194. Meyer, M.F., Wedemeyer, H., Monazahian, M., Dreesman, J., Manns, M.P. & Lehmann, M. (2007). Prevalence of hepatitis C in a German prison for young men in relation to country of birth. *Epidemiology & Infection* **135**, 274–280.
195. Hassan, M., Selimovic, D., Ghozlan, H. & Abdelkader, O. (2009). Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. *Hepatology* **49**, 1469–1482.
196. Phan, T., Beran, R.K., Peters, C., Lorenz, I. & Lindenbach, B.D. (2009). Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-4A enzyme complexes. *Journal of Virology* **83**, 8379–8395.
197. Vieyres, G., Angus, A.G., Haberstroh, A., Baumert, T.F., Dubuisson, J. & Patel, A.H. (2009). Rapid synchronization of hepatitis C virus infection by magnetic adsorption. *Journal of Virological Methods* **157**, 69–79.
198. Cao, W., Sun, B., Feitelson, M.A., Wu, T., Tur-Kaspa, R. & Fan, Q. (2009). Hepatitis C virus targets overexpression of arginase I in hepatocarcinogenesis. *International Journal of Cancer* **124**, 2886–2892.
199. Yamashita, T., Kaneko, S., Hashimoto, S., Sato, T., Nagai, S., Toyoda, N., Suzuki, T., Kobayashi, K. &

- Matsushima, K. (2001). Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. *Biochemical & Biophysical Research Communications* **282**, 647–654.
200. Jones, C.T., Murray, C.L., Eastman, D.K., Tassello, J. & Rice, C.M. (2007). Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. *Journal of Virology* **81**, 8374–8383.
201. Jirasko, V., Montserret, R., Appel, N., Janvier, A., Eustachi, L., Brohm, C., Steinmann, E., Pieteschmann, T., Penin, F. & Bartenschlager, R. (2008). Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. *Journal of Biological Chemistry* **283**, 28,546–28,562.
202. Welbourn, S., Jirasko, V., Breton, V., Reiss, S., Penin, F., Bartenschlager, R. & Pause, A. (2009). Investigation of a role for lysine residues in non-structural proteins 2 and 2/3 of the hepatitis C virus for their degradation and virus assembly. *Journal of General Virology* **90**, 1071–1080.
203. Yi, M., Ma, Y., Yates, J. & Lemon, S.M. (2009). Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. *PLoS Pathogens* **5**, e1000403.
204. Arumugaswami, V., Remenyi, R., Kanagavel, V., Sue, E.Y., Ngoc Ho, T., Liu, C., Fontanes, V., Dasgupta, A. & Sun, R. (2008). High-resolution functional profiling of hepatitis C virus genome. *PLoS Pathogens* **4**, e1000182.
205. Wohnsland, A., Hofmann, W.P. & Sarrazin, C. (2007). Viral determinants of resistance to treatment in patients with hepatitis C. *Clinical Microbiology Reviews* **20**, 23–38.
206. Katsarou, K., Serti, E., Tsitoura, P., Lavdas, A.A., Varaklioti, A., Pickl-Herk, A.M., Blaas, D., Oz-Arslan, D., Zhu, R., Hinterdorfer, P., Mavromara, P. & Georgopoulou, U. (2009). Green fluorescent protein-tagged HCV non-enveloped capsid like particles: Development of a new tool for tracking HCV core uptake. *Biochimie* **91**, 903–915.
207. Vassilaki, N. & Mavromara, P. (2009). The HCV ARFP/F/core+1 protein: Production and functional analysis of an unconventional viral product. *IUBMB Life* **61**, 739–752.
208. Asselah, T., Bieche, I., Sabbagh, A., Bedossa, P., Moreau, R., Valla, D., Vidaud, M. & Marcellin, P. (2009). Gene expression and hepatitis C virus infection. *Gut* **58**, 846–858.
209. Huang, H., Shiffman, M.L., Cheung, R.C., Layden, T.J., Friedman, S., Abar, O.T., Yee, L., Chokkalingam, A.P., Schrodi, S.J., Chan, J., Catanese, J.J., Leong, D.U., Ross, D., Hu, X., Monto, A., McAllister, L.B., Broder, S., White, T., Sninsky, J.J. & Wright, T.L. (2006). Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. *Gastroenterology* **130**, 1679–1687.
210. Huang, H., Shiffman, M.L., Friedman, S., Venkatesh, R., Bzowej, N., Abar, O.T., Rowland, C.M., Catanese, J.J., Leong, D.U., Sninsky, J.J., Layden, T.J., Wright, T.L., White, T. & Cheung, R.C. (2007). A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. *Hepatology* **46**, 297–306.
211. Liu, H.C., Hicks, J. & Yoo, D. (2008). Proteomic dissection of viral pathogenesis. *Developments in Biologicals* **132**, 43–53.
212. Vogt, M., Lang, T., Frosner, G., Klingler, C., Sendl, A.F., Zeller, A., Wiebecke, B., Langer, B., Meisner, H. & Hess, J. (1999). Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *New England Journal of Medicine* **341**, 866–870.
213. Deuffic-Burban, S., Poynard, T. & Valleron, A.J. (2002). Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. *Journal of Viral Hepatitis* **9**, 114–122.
214. Minola, E., Prati, D., Suter, F., Maggiolo, F., Caprioli, F., Sonzogni, A., Fraquelli, M., Paggi, S. & Conte, D. (2002). Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. *Blood* **99**, 4588–4591.
215. Di Martino, V., Lebray, P., Myers, R.P., Pannier, E., Paradis, V., Charlotte, F., Moussalli, J., Thabut, D., Buffet, C. & Poynard, T. (2004). Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure. *Hepatology* **40**, 1426–1433.
216. Wiese, M., Berr, F., Lafrenz, M., Porst, H. & Oesen, U. (2000). Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. *Hepatology* **32**, 91–96.
217. Kenny-Walsh, E. (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. *New England Journal of Medicine* **340**, 1228–1233.
218. Sterling, R.K., Stravitz, R.T., Luketic, V.A., Sanyal, A.J., Contos, M.J., Mills, A.S. & Shiffman, M.L. (2004). A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. *Clinical Gastroenterology & Hepatology* **2**, 469–473.
219. Wiley, T.E., Brown, J. & Chan, J. (2002). Hepatitis C infection in African Americans: Its natural history and histological progression. *American Journal of Gastroenterology* **97**, 700–706.
220. Tillmann, H.L., Chen, D.F., Trautwein, C., Kliem, V., Grundey, A., Berning-Haag, A., Boker, K., Kubicka, S., Pastucha, L., Stangel, W. & Manns, M.P. (2001). Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. *Gut* **48**, 714–718.
221. Kuzushita, N., Hayashi, N., Moribe, T., Katayama, K., Kanto, T., Nakatani, S., Kaneshige, T., Tatsumi, T., Ito, A., Mochizuki, K., Sasaki, Y., Kasahara, A. & Hori, M. (1998). Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. *Hepatology* **27**, 240–244.
222. Promrat, K., McDermott, D.H., Gonzalez, C.M., Kleiner, D.E., Koziol, D.E., Lessie, M., Merrell, M., Soza, A., Heller, T., Ghany, M., Park, Y., Alter, H.J., Hoofnagle, J.H., Murphy, P.M. & Liang, T.J. (2003). Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. *Gastroenterology* **124**, 352–360.
223. Kanzler, S., Baumann, M., Schirmacher, P., Dries, V., Bayer, E., Gerken, G., Dienes, H.P. & Lohse, A.W. (2001). Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. *Journal of Viral Hepatitis* **8**, 430–437.
224. Adinolfi, L.E., Gambardella, M., Andreatina, A.,

- Tripodi, M.F., Utili, R. & Ruggiero, G. (2001). Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* **33**, 1358–1364.
225. Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Adinolfi, L.E., Asselah, T., Jonsson, J.R., Smedile, A., Terrault, N., Pazienza, V., Giordani, M.T., Giostra, E., Sonzogni, A., Ruggiero, G., Marcellin, P., Powell, E.E., George, J. & Negro, F. (2006). Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. *Gastroenterology* **130**, 1636–1642.
226. Monto, A., Alonzo, J., Watson, J.J., Grunfeld, C. & Wright, T.L. (2002). Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. *Hepatology* **36**, 729–736.
227. Ratziu, V., Munteanu, M., Charlotte, F., Bonyhay, L. & Poynard, T. (2003). Fibrogenic impact of high serum glucose in chronic hepatitis C. *Journal of Hepatology* **39**, 1049–1055.
228. Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D. & Berenguer, J. (2002). Contribution of obesity to hepatitis C-related fibrosis progression. *American Journal of Gastroenterology* **97**, 2408–2414.
229. Hourigan, L.F., Macdonald, G.A., Purdie, D., Whitehall, V.H., Shorthouse, C., Clouston, A. & Powell, E.E. (1999). Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* **29**, 1215–1219.
230. Sulkowski, M.S. (2007). The HIV-coinfected patient: Managing viral hepatitis. *Journal of Acquired Immune Deficiency Syndromes* **45**, Suppl. 2, S36–S37.
231. Soto, B., Sanchez-Quijano, A., Rodrigo, L., del Olmo, J.A., Garcia-Bengochea, M., Hernandez-Quero, J., Rey, C., Abad, M.A., Rodriguez, M., Sales Gilabert, M., Gonzalez, F., Miron, P., Caruz, A., Relimpio, F., Torronteras, R., Leal, M. & Lissen, E. (1997). Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *Journal of Hepatology* **26**, 1–5.
232. Thomas, D.L., Shih, J.W., Alter, H.J., Vlahov, D., Cohn, S., Hoover, D.R., Cheung, L. & Nelson, K.E. (1996). Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. *Journal of Infectious Diseases* **174**, 690–695.
233. Ragni, M.V. & Belle, S.H. (2001). Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *Journal of Infectious Diseases* **183**, 1112–1115.
234. Graham, C.S., Baden, L.R., Yu, E., Mrus, J.M., Carnie, J., Heeren, T. & Koziel, M.J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. *Clinical Infectious Diseases* **33**, 562–569.
235. Gaeta, G.B., Stornaiuolo, G., Precone, D.F., Lobello, S., Chiaramonte, M., Stroffolini, T., Colucci, G. & Rizzetto, M. (2003). Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. *Journal of Hepatology* **39**, 1036–1041.
236. Pontisso, P., Gerotto, M., Benvegna, L., Chemello, L. & Alberti, A. (1998). Coinfection by hepatitis B virus and hepatitis C virus. *Antiviral Therapy* **3**, 137–142.
237. Derbala, M.F., Al Kaabi, S.R., El Dweik, N.Z., Pasic, F., Butt, M.T., Yakoob, R., Al-Marri, A., Amer, A.M., Morad, N. & Bener, A. (2006). Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. *World Journal of Gastroenterology* **12**, 5692–5698.
238. Kamal, S., Madwar, M., Bianchi, L., Tawil, A.E., Fawzy, R., Peters, T. & Rasenack, J.W. (2000). Clinical, virological and histopathological features: Long-term follow-up in patients with chronic hepatitis C co-infected with *S. mansoni*. *Liver* **20**, 281–289.
239. Bonkovsky, H.L., Banner, B.F. & Rothman, A.L. (1997). Iron and chronic viral hepatitis. *Hepatology* **25**, 759–768.
240. Mori, M., Hara, M., Wada, I., Hara, T., Yamamoto, K., Honda, M. & Naramoto, J. (2000). Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. *American Journal of Epidemiology* **151**, 131–139.
241. Pessione, F., Ramond, M.J., Njapoum, C., Duchatelle, V., Degott, C., Erlinger, S., Rueff, B., Valla, D.C. & Degos, F. (2001). Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. *Hepatology* **34**, 121–125.
242. Hutchinson, S.J., Bird, S.M. & Goldberg, D.J. (2005). Influence of alcohol on the progression of hepatitis C virus infection: A meta-analysis. *Clinical Gastroenterology & Hepatology* **3**, 1150–1159.
243. Harris, D.R., Gonin, R., Alter, H.J., Wright, E.C., Buskell, Z.J., Hollinger, F.B. & Seeff, L.B. (2001). The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Annals of Internal Medicine* **134**, 120–124.
244. Ostapowicz, G., Watson, K.J., Locarnini, S.A. & Desmond, P.V. (1998). Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. *Hepatology* **27**, 1730–1735.
245. Layden-Almer, J.E., Ribeiro, R.M., Wiley, T., Perelson, A.S. & Layden, T.J. (2003). Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. *Hepatology* **37**, 1343–1350.
246. Asselah, T., Bieche, I., Laurendeau, I., Paradis, V., Vidaud, D., Degott, C., Martinot, M., Bedossa, P., Valla, D., Vidaud, M. & Marcellin, P. (2005). Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. *Gastroenterology* **129**, 2064–2075.
247. Bieche, I., Asselah, T., Laurendeau, I., Vidaud, D., Degott, C., Paradis, V., Bedossa, P., Valla, D.C., Marcellin, P. & Vidaud, M. (2005). Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. *Virology* **332**, 130–144.
248. Shao, R.X., Hoshida, Y., Otsuka, M., Kato, N., Tateishi, R., Teratani, T., Shiina, S., Taniguchi, H., Moriyama, M., Kawabe, T. & Omata, M. (2005). Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. *World Journal of Gastroenterology* **11**, 1995–1999.
249. Lau, D.T., Luxon, B.A., Xiao, S.Y., Beard, M.R. &

- Lemon, S.M. (2005). Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. *Hepatology* **42**, 273–281.
250. Smith, M.W., Walters, K.A., Korth, M.J., Fitzgibbon, M., Proll, S., Thompson, J.C., Yeh, M.M., Shuhart, M.C., Furlong, J.C., Cox, P.P., Thomas, D.L., Phillips, J.D., Kushner, J.P., Fausto, N., Carithers, R.L.J. & Katze, M.G. (2006). Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. *Gastroenterology* **130**, 179–187.
251. Honda, M., Kaneko, S., Kawai, H., Shirota, Y. & Kobayashi, K. (2001). Differential gene expression between chronic hepatitis B and C hepatic lesion. *Gastroenterology* **120**, 955–966.
252. Pelkmans, L., Fava, E., Grabner, H., Hannus, M., Habermann, B., Krausz, E. & Zerial, M. (2005). Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. *Nature, London* **436**, 78–86.
253. Carpenter, A.E. & Sabatini, D.M. (2004). Systematic genome-wide screens of gene function. *Nature Reviews Genetics* **5**, 11–22.
254. Erfle, H., Simpson, J.C., Bastiaens, P.I. & Pepperkok, R. (2004). siRNA cell arrays for high-content screening microscopy. *BioTechniques* **37**, 454–458, 460, 462.
255. Matula, P., Kumar, A., Wörz, I., Erfle, H., Bartschlag, R., Eils, R. & Rohr, K. (2009). Single-cell-based image analysis of high-throughput cell array screens for quantification of viral infection. *Cytometry A* **75**, 309–318.
256. Pfeffer, S. & Baumert, T.F. (2009). Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. *Journal of Hepatology* **51**, 606–609.
257. Vaillancourt, F.H., Pilote, L., Cartier, M., Lippens, J., Liuzzi, M., Bethell, R.C., Cordingley, M.G. & Kukolj, G. (2009). Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. *Virology* **387**, 5–10.
258. Ahn, J., Chung, K.S., Kim, D.U., Won, M., Kim, L., Kim, K.S., Nam, M., Choi, S.J., Kim, H.C., Yoon, M., Chae, S.K. & Hoe, K.L. (2004). Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. *Journal of Biochemistry & Molecular Biology* **37**, 741–748.
259. Mannova, P., Fang, R., Wang, H., Deng, B., McIntosh, M.W., Hanash, S.M. & Beretta, L. (2006). Modification of host lipid raft proteome upon hepatitis C virus replication. *Molecular & Cellular Proteomics* **5**, 2319–2325.
260. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K. & Ganz, T. (2004). IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *Journal of Clinical Investigation* **113**, 1271–1276.
261. Aoki, C.A., Rossaro, L., Ramsamooj, R., Brandhagen, D., Burritt, M.F. & Bowlus, C.L. (2005). Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. *Journal of Clinical Gastroenterology* **39**, 71–74.
262. Calvisi, D.F., Ladu, S., Gorden, A., Farina, M., Lee, J.S., Conner, E.A., Schroeder, I., Factor, V.M. & Thorgeirsson, S.S. (2007). Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. *Journal of Clinical Investigation* **117**, 2713–2722.
263. Li, X., Hui, A.M., Sun, L., Hasegawa, K., Torzilli, G., Minagawa, M., Takayama, T. & Makuuchi, M. (2004). p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. *Clinical Cancer Research* **10**, 7484–7489.
264. Yoshida, T., Ogata, H., Kamio, M., Joo, A., Shiraiishi, H., Tokunaga, Y., Sata, M., Nagai, H. & Yoshimura, A. (2004). SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. *Journal of Experimental Medicine* **199**, 1701–1707.
265. Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraiishi, H., Iida, M., Kobayashi, T. & Yoshimura, A. (2006). Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. *Oncogene* **25**, 2520–2530.
266. Di Gioia, S., Bianchi, P., Destro, A., Grizzi, F., Malesci, A., Laghi, L., Levrero, M., Morabito, A. & Roncalli, M. (2006). Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. *BMC Cancer* **6**, 89.
267. Nishida, N., Nagasaka, T., Nishimura, T., Ikai, I., Boland, C.R. & Goel, A. (2008). Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. *Hepatology* **47**, 908–918.
268. Ura, S., Honda, M., Yamashita, T., Ueda, T., Takatori, H., Nishino, R., Sunakozaka, H., Sakai, Y., Horimoto, K. & Kaneko, S. (2009). Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. *Hepatology* **49**, 1098–1112.
269. Yano, M., Ikeda, M., Abe, K.I., Kawai, Y., Kuroki, M., Mori, K., Dansako, H., Ariumi, Y., Ohkoshi, S., Aoyagi, Y. & Kato, N. (2009). Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. *Hepatology* **50**, 678–688.
270. Choi, J., Forman, H.J., Ou, J.H., Lai, M.M., Seronello, S. & Nandipati, A. (2006). Redox modulation of the hepatitis C virus replication complex is calcium dependent. *Free Radical Biology & Medicine* **41**, 1488–1498.
271. Waris, G. & Siddiqui, A. (2005). Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: Role of prostaglandin E2 in RNA replication. *Journal of Virology* **79**, 9725–9734.
272. Choi, J., Lee, K.J., Zheng, Y., Yamaga, A.K., Lai, M.M. & Ou, J.H. (2004). Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. *Hepatology* **39**, 81–89.
273. Trujillo-Murillo, K., Rincon-Sanchez, A.R., Martinez-Rodriguez, H., Bosques-Padilla, F., Ramos-Jimenez, J., Barrera-Saldana, H.A., Rojkind, M. & Rivas-Estilla, A.M. (2008). Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. *Hepatology* **47**, 1462–1472.
274. Huang, Y., Chen, X.C., Konduri, M., Fomina, N., Lu, J., Jin, L., Kolykhalov, A. & Tan, S.L. (2006). Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. *Hepatology* **43**, 81–90.
275. Takeshita, M., Ishida, Y.I., Akamatsu, E., Ohmori, Y., Sudoh, M., Uto, H., Tsubouchi, H. & Kataoka,

- H. (2009). Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. *Journal of Biological Chemistry* **284**, 21,165–21,176.
276. Ujino, S., Yamaguchi, S., Shimotohno, K. & Takaku, H. (2009). Heat-shock protein 90 is essential for stabilization of the hepatitis C virus non-structural protein NS3. *Journal of Biological Chemistry* **284**, 6841–6846.
277. Wagner, R., Larson, D.P., Beno, D.W., Bosse, T.D., Darbyshire, J.F., Gao, Y., Gates, B.D., He, W., Henry, R.F., Hernandez, L.E., Hutchinson, D.K., Jiang, W.W., Kati, W.M., Klein, L.L., Koev, G., Kohlbrenner, W., Krueger, A.C., Liu, J., Liu, Y., Long, M.A., Maring, C.J., Masse, S.V., Middleton, T., Montgomery, D.A., Pratt, J.K., Stuart, P., Molla, A. & Kempf, D.J. (2009). Inhibitors of hepatitis C virus polymerase: Synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines. *Journal of Medicinal Chemistry* **52**, 1659–1669.
278. Wang, S.Y., Tseng, C.P., Tsai, K.C., Lin, C.F., Wen, C.Y., Tsay, H.S., Sakamoto, N., Tseng, C.H. & Cheng, J.C. (2009). Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from *Lonicera hypoglauca* Miq. *Biochemical & Biophysical Research Communications* **385**, 230–235.
279. Ikeda, M., Mori, K., Ariumi, Y., Dansako, H. & Kato, N. (2009). Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha. *FEBS Letters* **583**, 1434–1438.
280. Zhang, Y.L., Guo, Y.J., Bin, L. & Sun, S.H. (2009). Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. *Journal of Hepatology* **51**, 29–38.
281. Liu, Z., Yang, F., Robotham, J.M. & Tang, H. (2009). Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. *Journal of Virology* **83**, 6554–6565.
282. Liu, H.M., Aizaki, H., Choi, K.S., Machida, K., Ou, J.J. & Lai, M.M. (2009). SYNCRIP (synaptotagmin-binding, cytoplasmic RNA-interacting protein) is a host factor involved in hepatitis C virus RNA replication. *Virology* **386**, 249–256.
283. Locarnini, S.A. & Bartholomeusz, A. (2002). Advances in hepatitis C: What is coming in the next 5 years? *Journal of Gastroenterology & Hepatology* **17**, 442–447.
284. Chen, Y.R., Chen, T.Y., Zhang, S.L., Lin, S.M., Zhao, Y.R., Ye, F., Zhang, X., Shi, L., Dang, S.S. & Liu, M. (2009). Identification of a novel protein binding to hepatitis C virus core protein. *Journal of Gastroenterology & Hepatology* **24**, 1300–1304.
285. Gondeau, C., Pichard-Garcia, L. & Maurel, P. (2009). Cellular models for the screening and development of anti-hepatitis C virus agents. *Pharmacology & Therapeutics* **124**, 1–22.
286. Heck, J.A., Meng, X. & Frick, D.N. (2009). Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. *Biochemical Pharmacology* **77**, 1173–1180.
287. Paeshuyse, J., Kaul, A., De Clercq, E., Rosenwirth, B., Dumont, J.M., Scalfaro, P., Bartenschlager, R. & Neyts, J. (2006). The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication *in vitro*. *Hepatology* **43**, 761–770.
288. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. (2003). Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* **38**, 1282–1288.
289. Nakagawa, M., Sakamoto, N., Enomoto, N., Tanabe, Y., Kanazawa, N., Koyama, T., Kurosaki, M., Maekawa, S., Yamashiro, T., Chen, C.H., Itsui, Y., Kakinuma, S. & Watanabe, M. (2004). Specific inhibition of hepatitis C virus replication by cyclosporin A. *Biochemical & Biophysical Research Communications* **313**, 42–47.
290. Goodchild, A., Nopper, N., Craddock, A., Law, T., King, A., Fanning, G., Rivory, L. & Passioura, T. (2009). Primary leukocyte screens for innate immune agonists. *Journal of Biomolecular Screening* **14**, 723–730.
291. Mondal, R., Koev, G., Pilot-Matias, T., He, Y., Ng, T., Kati, W. & Molla, A. (2009). Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well. *Antiviral Research* **82**, 82–88.
292. Ziegler, S., Kronenberger, B., Albrecht, B.A., Kaul, A., Gamer, A.L., Klein, C.D. & Hartmann, R.W. (2009). Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors. *Journal of Biomolecular Screening* **14**, 620–626.
293. Aly, H.H., Qi, Y., Atsuzawa, K., Usuda, N., Takada, Y., Mizokami, M., Shimotohno, K. & Hijikata, M. (2009). Strain-dependent viral dynamics and virus–cell interactions in a novel *in vitro* system supporting the life cycle of blood-borne hepatitis C virus. *Hepatology* **50**, 689–696.
294. Iro, M., Witteveldt, J., Angus, A.G., Woerz, I., Kaul, A., Bartenschlager, R. & Patel, A.H. (2009). A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. *Antiviral Research* **83**, 148–155.
295. Tai, A.W., Benita, Y., Peng, L.F., Kim, S.S., Sakamoto, N., Xavier, R.J. & Chung, R.T. (2009). A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. *Cell Host & Microbe* **5**, 298–307.
296. Ng, T.I., Mo, H., Pilot-Matias, T., He, Y., Koev, G., Krishnan, P., Mondal, R., Pithawalla, R., He, W., Dekhtyar, T., Packer, J., Schurdak, M. & Molla, A. (2007). Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. *Hepatology* **45**, 1413–1421.
297. Randall, G., Panis, M., Cooper, J.D., Tellinghuisen, T.L., Sukhodolets, K.E., Pfeffer, S., Landthaler, M., Landgraf, P., Kan, S., Lindenbach, B.D., Chien, M., Weir, D.B., Russo, J.J., Ju, J., Brownstein, M.J., Sheridan, R., Sander, C., Zavolan, M., Tuschl, T. & Rice, C.M. (2007). Cellular cofactors affecting hepatitis C virus infection and replication. *Proceedings of the National Academy of Sciences of the USA* **104**, 12,884–12,889.
298. Supekova, L., Supek, F., Lee, J., Chen, S., Gray, N., Pezacki, J.P., Schlapbach, A. & Schultz, P.G. (2008). Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. *Journal of Biological Chemistry* **283**, 29–36.
299. Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G.A., Grazi, G.L., Giovannini, C., Croce, C.M., Bolondi, L. & Negrini, M. (2008). MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular

- carcinoma. *Oncogene* **27**, 5651–5661.
300. Gramantieri, L., Ferracin, M., Fornari, F., Veronese, A., Sabbioni, S., Liu, C.G., Calin, G.A., Giovannini, C., Ferrazzi, E., Grazi, G.L., Croce, C.M., Bolondi, L. & Negrini, M. (2007). Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Research* **67**, 6092–6099.
 301. Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T. & Patel, T. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology* **133**, 647–658.
 302. Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanou, T. & Shimotohno, K. (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. *Oncogene* **25**, 2537–2545.
 303. Jiang, J., Gusev, Y., Aderca, I., Mettler, T.A., Nagorney, D.M., Brackett, D.J., Roberts, L.R. & Schmittgen, T.D. (2008). Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. *Clinical Cancer Research* **14**, 419–427.
 304. Mehta, P., Ploutz-Snyder, R., Nandi, J., Rawlins, S.R., Sanderson, S.O. & Levine, R.A. (2008). Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. *American Journal of Gastroenterology* **103**, 928–936.
 305. Huang, Y., Yang, H., Borg, B.B., Su, X., Rhodes, S.L., Yang, K., Tong, X., Tang, G., Howell, C.D., Rosen, H.R., Thio, C.L., Thomas, D.L., Alter, H.J., Sapp, R.K. & Liang, T.J. (2007). A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. *Proceedings of the National Academy of Sciences of the USA* **104**, 985–990.
 306. Morgan, T.R., Lambrecht, R.W., Bonkovsky, H.L., Chung, R.T., Naishadham, D., Sterling, R.K., Fontana, R.J., Lee, W.M., Ghany, M.G., Wright, E.C. & O'Brien, T.R. (2008). DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. *Journal of Hepatology* **49**, 548–556.
 307. Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.L., Coltescu, C., Heathcote, J., Edwards, A.M. & McGilvray, I.D. (2005). Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. *Gastroenterology* **128**, 1437–1444.
 308. Feld, J.J., Nanda, S., Huang, Y., Chen, W., Cam, M., Pusek, S.N., Schweigler, L.M., Theodore, D., Zacks, S.L., Liang, T.J. & Fried, M.W. (2007). Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. *Hepatology* **46**, 1548–1563.
 309. Hayashida, K., Daiba, A., Sakai, A., Tanaka, T., Kaji, K., Inaba, N., Ando, S., Kajiyama, N., Terasaki, H., Abe, A., Ogasawara, M., Kohara, M., Harada, M., Okanou, T., Ito, S. & Kaneko, S. (2005). Pre-treatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. *Clinical Gastroenterology & Hepatology* **3**, 1253–1259.
 310. Persico, M., Capasso, M., Russo, R., Persico, E., Croce, L., Tiribelli, C. & Iolascon, A. (2008). Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. *Gut* **57**, 507–515.
 311. Aborsangaya, K.B., Dembinski, I., Khatkar, S., Alphonse, M.P., Nickerson, P. & Rempel, J.D. (2007). Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: Interaction with IL-10 gene polymorphisms. *Hepatology* **45**, 623–630.
 312. Larcombe, L., Rempel, J.D., Dembinski, I., Tinckam, K., Rigatto, C. & Nickerson, P. (2005). Differential cytokine genotype frequencies among Canadian Aboriginal and Caucasian populations. *Genes & Immunity* **6**, 140–144.
 313. Rempel, J.D., Aborsangaya, K.B., Alphonse, M.P. & Minuk, G.Y. (2009). The influence of North American Aboriginal ethnicity on pro-inflammatory and anti-inflammatory cytokine responses to IFN-alpha. *Journal of Viral Hepatitis* **16**, 292–297.
 314. Kawai, Y., Ikeda, M., Abe, K.I., Yano, M., Ariumi, Y., Dansako, H., Yamamoto, K. & Kato, N. (2009). Development of a hepatitis C virus relapse model using genome-length hepatitis C virus ribonucleic acid-harboring cells possessing the interferon-alpha-resistance phenotype. *Hepatology Research* **39**, 898–909.
 315. Byers, A.M., Tapia, T.M., Sassano, E.R. & Wittman, V. (2009). *In vitro* antibody response to tetanus in the MIMIC system is a representative measure of vaccine immunogenicity. *Biologicals* **37**, 148–151.
 316. Shudo, E., Ribeiro, R.M. & Perelson, A.S. (2009). Modeling HCV kinetics under therapy using PK and PD information. *Expert Opinion on Drug Metabolism & Toxicology* **5**, 321–332.
 317. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. & Perelson, A.S. (1998). Hepatitis C viral dynamics *in vivo* and the antiviral efficacy of interferon-alpha therapy. *Science, New York* **282**, 103–107.
 318. Perelson, A.S. & Ribeiro, R.M. (2008). Estimating drug efficacy and viral dynamic parameters: HIV and HCV. *Statistics in Medicine* **27**, 4647–4657.
 319. Perelson, A.S., Herrmann, E., Micol, F. & Zeuzem, S. (2005). New kinetic models for the hepatitis C virus. *Hepatology* **42**, 749–754.
 320. Herrmann, E. & Zeuzem, S. (2006). The kinetics of hepatitis C virus. *European Journal of Gastroenterology & Hepatology* **18**, 339–342.
 321. Dixit, N.M. & Perelson, A.S. (2006). The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. *Cellular & Molecular Life Sciences* **63**, 832–842.